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ABSTRACT

The subject technology relates to arylquinoline compounds
and their use for treating cancer or cancer metastasis. The
compounds of the subject technology promote cells to
secrete a pro-apoptotic tumor suppressor, i.e., prostate apop
tosis response-4 (Par-4), which in tum promote apoptosis in
cancer cells or metastatic cells.
13 Claims, 5 Drawing Sheets
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X = ortho-F, Y = NMe2 (Arylquin 1)
X = meta-F, Y = NMe2 (Arylquin 2)
X = para-F, Y = NMe2 (Aryl1uin 3)
X = H, Y = NMe2 (Arylquin l
X = ortho-F, Y = H (Arylquin 8)
e, f
..__...
Z = O (Arylquin 4) --, c
Z = S (Arylquin 5) .......i

Arylquin 6

: I di
H

S� N ri20\120ri2NH
O Biotinylated Arylquin 9 O
Legend of reagents: a, arylacetonitrile, terl-BuOK, DMF, 90°C, 3-4h; b,° 2(2'
fluorophenyl)acetyl chloride, Et3N, reflux 2h and then K2C03, DMF, 90 C, 4h; c, 2,4-bis(4methoxyphenyl)-2,4-dithioxo-1,3,2,4-dithiadiphosphetane (Lawesson's reagent), dioxane,
reflux 5h; d, (+)-biotinyl-iodoacetamidyl-°3,6-dioxaoctanediamine, K2C03, DMF, 12h; e,
POCl3, reflux, 3h; f, Zn, CH3C02H, 75 C, 1 h.
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ARYLQUINOLINE AND ANALOG
COMPOUNDS AND USE THEREOF TO
TREAT CANCER
CROSS-REFERENCE TO RELATED
APPLICATION
This application is a U.S. National Phase under 35 U.S.C.
§371 oflnternational Application No. PCT/US2014/066796,
filed Nov. 21, 2014, which claims the benefit of U.S.
Provisional Application No. 61/907,817, filed Nov. 22,
2013, the entire disclosures of which are hereby incorpo
rated by reference herein.
STATEMENT REGARDING FEDERALLY
SPONSORED RESEARCH
This work was supported by National Center for Research
Resources in a grant entitled "COBRE Center for Biomedical Research Excellence" grant P20 RR020171; and NIH/
NCI ROI CA60872 (to VMR). The government has certain
rights in the subject technology.
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TECHNICAL FIELD
The present invention relates to compounds that treat
cancer and/or treat or prevent cancer metastasis. In particu
lar, the subject technology is directed to arylquinoline com
pounds and analogs thereof such as arylquinolone or aryl
thioquinolone compounds, described as "arylquin"
compounds, that promote cells to secrete a pro-apoptotic
tumor suppressor, such as prostate apoptosis response-4
(Par-4), which promotes apoptosis in cancer cells or meta
static cells.
BACKGROUND
Lung cancer is the most frequently diagnosed cancer and
the leading cause of cancer-related deaths in the world. The
most common alterations in lung cancer include activating
mutations in ras genes and inactivating mutations in the p53
gene. Lung tumor cells with p53 mutations or deletions often
develop resistance to chemotherapy and radiation therapy,
leading ultimately to the death of the patients. Notably, such
p53-deficient cancer cells are susceptible to apoptosis by the
proapoptotic tumor suppressor, Par-4.
Par-4 is a tumor suppressor protein that induces apoptosis
in diverse cancer cells but not in normal cells. Par-4 is
ubiquitously expressed in normal cells and tissues, but is
sequestered by an intermediary filament protein, vimentin,
and hence, circulating levels of Par-4 are generally low. If it
were secreted by normal cells at appreciably higher levels
than normal, certain cancer cells would be susceptible to its
effects. Extracellular Par-4 binds a receptor GRP78, which
appears only on the cancer cell surface, and induces apop
tosis by caspase-dependent mechanisms. In contrast, normal
cells express low to undetectable levels of basal or inducible
cell-surface GRP78 and are resistant to apoptosis by extra
cellular Par-4.
Therefore, there is a need for compounds that are Par-4
secretagogues and promote the secretion of Par-4 which in
turn promotes apoptosis in cancer cells and metastatic cells.
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or a pharmaceutically acceptable salt thereof; wherein n is 1,
2, 3, 4, 5, or 6, for each NR 1 R2, R 1 and R2 are independently
H, alkyl, alkoxy, aryl, heteroaryl; Ar is aryl or heteroaryl,
which can be further substituted with halogen, amino, alky
lamino, dialkylamino, arylalkylamino, N-oxides of dialky
lamino, trialkylammonium, mercapto, alkylthio, alkanoyl,
nitro, nitrosyl, cyano, alkoxy, alkenyloxy, aryl, heteroaryl,
sulfonyl, sulfonamide, CONR3R4, NR3CO(R4), NR3COO
(R4), NR3 CONR4R5 where R3 , R4, R5 , are independently, H,
alkyl, aryl, heteroaryl or a fluorine; X represents halogen; m
is 1, 2, 3, 4, or 5.
In one aspect of the present disclosure, n is 1 to 3; m is
1 to 3 and X is selected from fluorine or chlorine, e.g. X is
one, two or three fluorine substituents, or X is one, two or
three chlorine substituents, or X represents at least one
fluorine and at least one chlorine on Ar. In various embodiments, the compound of Formula (I) includes wherein n is
at least 2 or 2 and one NR 1 R2 group is at the 2 position of
the quinoline ring and another NR 1 R2 group is at the 7
position of the quinoline ring; and Ar-Xm is at the 3 position
of the quinoline ring. In other embodiments, Ar is phenyl, m
is 2 and X is selected from fluoro or chloro. In further
embodiments, m is 1 and the Ar-Xm group at the 3 position
of the quinoline ring is an ortho fluoro or ortho chloro phenyl
group. In still other embodiments, the Ar-Xm group at the 3
position is a halogen substituted heteroaryl, e.g., pyridyl,
pyrolidyl, piperidyl, or pyrimidyl having one or more halo
gen substituents. For each of the embodiments, each of R 1
and R2 of each NR 1 R2 can be independently H, or a lower
alkyl.
In another aspect, the subject technology relates to compounds where the Ar-Xm group is located at the 3 position
of the quinoline, quinolone or thioquinolone ring and Ar is
a phenyl group such as shown in formulas (II) or (III):

60

(II)
I
--Xm
1

SUMMARY OF THE DISCLOSURE
Advantages of the subject technology include arylquino
line and analog compounds and compositions for the treat-

ment of cancer or for the treatment or inhibition of cancer
metastasis in a subject in need thereof comprising adminis
tering to the subject an effective amount of the compound or
a pharmaceutically acceptable salt thereof or a composition
thereof.
Other advantages of the subject technology include com
pounds for use in promoting the secretion of Prostate
Apoptosis Response-4 (PAR-4) from cells or for use in
promoting apoptosis of a cancer cell in a subject comprising
administering to the subject an effective amount of an
arylquinoline or analog compound or a pharmaceutically
acceptable salt thereof or a composition thereof.
In one aspect of the subject technology, the arylquinoline
is a compound according to Formula (I):

65
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-continued

In another aspect, the subject technology relates to a kit
which includes the compounds of the subject technology. In
an embodiment related to this aspect, the kit includes one or
more compounds of Formula(I),(II) and/or(II). In another
embodiment, the kit includes one or more other therapeutic
compounds for use in combination therapies.
Additional advantages of the subject technology will
become readily apparent to those skilled in this art from the
following detailed description, wherein only the preferred
embodiment of the disclosure is shown and described,
simply by way of illustration of the best mode contemplated
of carrying out the disclosure. As will be realized, the
disclosure is capable of other and different embodiments,
and its several details are capable of modifications in various
obvious respects, all without departing from the disclosure.
Accordingly, the drawings and description are to be regarded
as illustrative in nature, and not as restrictive.

(III)

5

or a pharmaceutically acceptable salt thereof. In Formulas
(II) and (III), Z is O or S; and n, R i , R2 , X and m are as
defined for the compound of Formula(I). The compounds of
Formula (III) are arylquinolones and arylthioquinolones
when Z is O or S, respectively, and are useful in the same
manner as the compounds according to Formula(I). For ease
of reference, the compounds of Formulas(I), (II), (III) will
be referred to herein as arylquinoline or arylquin com
pounds.
In various embodiments, the compounds of Formula(II)
and Formula(III) have n as 1, 2, or 3 and m as 1, 2, or 3,
e.g., the compounds include one NR1 R2 group at the 2
position of the quinoline ring and another NR1 R2 group at
the 7 position of the quinoline ring, and X is selected from
fluoro or chloro. In other embodiments, the compounds of
Formula(II) or(III) have n as 2, m as 2 and X selected from
fluoro or chloro. In still further embodiments, the com
pounds of Formula (II) or (III) have n as 2, m as 1 and X
selected as chloro or fluoro at the ortho position of the
phenyl ring. For each of the embodiments, each R 1 and R2
of each NR1 R2 can be independently H, or a lower alkyl.
Another aspect of the subject technology includes a
biotinylated derivative or other detectably labeled alterna
tive of each of Formulas(I), (II) and(III) and their various
embodiments.
In another aspect, the subject technology relates to phar
maceutical compositions of arylquinoline compounds, e.g.,
one or more compounds of Formula(I), Formula(II) and/or
Formula(III), and/or one or more pharmaceutically accept
able salts thereof, in combination with a pharmaceutical
additive, e.g., a pharmaceutically acceptable carrier and/or
excipient. In an embodiment related to this aspect, the
subject technology relates to a pharmaceutical composition
including an effective amount of at least one arylquinoline
compound.
In another aspect, the subject technology relates to a
method of treating cancer and/or treating or inhibiting
cancer metastasis in a subject, e.g., a human. In an embodi
ment relating to this aspect, a therapeutically effective
amount of one or more arylquinoline compounds, pharma
ceutical salts and/or compositions thereof is administered to
a subject in need thereof to treat cancer and/or treat or inhibit
cancer metastasis in the subject.
In another aspect, the subject technology relates to a
method for promoting secretion of Prostate Apoptosis
Response-4 (Par-4) from cells or promoting apoptosis of
cancer cells in a subject in need thereof by administering to
the subject an effective amount of one or more arylquinoline
compounds or compositions in accordance with the subject
technology.
In another aspect, the subject technology relates to a
method for screening for compounds that inhibit vimentin
binding to PAR-4, comprising exposing a solution including
vimentin and PAR-4 to a test compound and detecting the
level of vimentin-PAR-4 complex formation by Western blot
analysis, for example.
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The accompanying drawings, which are included to pro
vide further understanding of the subject technology and are
incorporated in and constitute a part of this specification,
illustrate aspects of the subject technology and together with
the description serve to explain the principles of the subject
technology.
FIG. 1 is an exemplary illustration showing methods for
synthesis of arylquinolines, arylquinolones, and arylthioqui
nolones.
FIG. 2 shows charts illustrating the induced apoptosis in
cancer cells by an arylquinoline of the present disclosure.
Normal cells (MEFs, HELs, HBEC, PrE, prostate stromal
cells PrS) or lung cancer cells (human A549 and H460,
mouse LLCl and KP7B) and prostate cancer cells (PC-3
MM2, DU145, LNCaP) were treated with the indicated
amounts(0.5, 1 and 10 µM) of Arylquin 1 or vehicle(V) for
24 h, and apoptosis was determined by ICC for active
caspase-3. Data shown represent mean values from three
independent experiments±s.d. Asterisks(**) or(*) indicate
statistical significance (P<0.0001) or (P<0.001), respec
tively, by the Student t test.
FIG. 3 shows apoptosis activity for an arylquinoline of the
present disclosure. Top: Cancer cells were co-cultured with
MEFs and treated with Arylquin 1(500 nM) or vehicle and
tested for apoptosis. Bottom: Serum from mice injected with
Arylquin 1 (Aq) or corn oil vehicle (V), was examined by
Western blot analysis(not shown). Aliquots of serum from
these mice were either directly added to the growth medium
of cells in culture, or incubated with the indicated antibody,
and then added to the growth medium of PC-3 MM2 cells to
test for apoptosis.
FIGS. 4A and 48 are bar graphs illustrating percent cell
surface GRP-78 expression and apoposis activity for an
arylquinoline of the present disclosure. FIG. 4A is a bar
graph showing cell surface GRP78 levels in cancer cells
treated with CM from MEFs exposed to Arylquin 1. Par4+/+ MEFs or Par-4-/- MEFs were treated with vehicle or
Arylquin 1 (500 nM) for 24 h. The CM from these MEFs
was incubated with the indicated cancer cells for 24 h. The
cancer cells were then subjected to FACS analysis for cell
surface GRP78 expression. Data shown represent mean
values of three experiments±s.d. Asterisks (**) or(*) indi
cate statistical si gnificance(P<0.0001) or(P<0.001), respec
tively, based on two-way ANOVA with data normality and
equality of variance assumptions. FIG. 48 is a bar graph
showing the apoptotic activity of secreted Par-4 is inhibited
by the presence of a neutralizing antibody against cell

US 9,873,670 B2
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surface GRP78. Par-4+/+ MEFs or Par-4-/- MEFs were
treated with vehicle or Arylquin 1 (Aq, 500 nM) for 24 h.
The CM from these cells was then treated with GRP78
antibody (GRP78 Ab) or control IgG antibody (Control Ab)
and incubated with the indicated cancer cells. After 24 h, the
cancer cells were scored for apoptosis by ICC for active
caspase-3. Apoptosis data shown represent mean values of
three experiments±s.d. Asterisks (**) or (*) indicate statis
tical significance (P<0.0001) or (P<0.001), respectively,
based on two-way ANOVA.
FIG. 5 is a bar graph showing apoptosis activity in PC-3
cells. The CM from Vim-/- MEFs was treated with the
indicated antibody (Ab) and tested for apoptosis of cancer
cells. The CM from Vim+/+ or Vim-/- cells served as
additional controls. Data shown represent mean values from
three independent experiments±s.d. Asterisks (**) indicate
statistical significance (P<0.0001) by the Student t test.
DETAILED DESCRIPTION OF THE
DISCLOSURE
In general, the subject technology relates to Par-4 secre
tagogues that induce the release of Par-4 from normal cells
thereby triggering the paracrine apoptosis of cancer cells. In
accordance with the subject technology, certain arylquino
line compounds have been identified as Par-4 secretagogues
which induce or promote Par-4 secretion at low (nanomolar)
concentrations from both normal lung fibroblasts and epi
thelial cells. The arylquinoline compounds and their pharmaceutically acceptable salts and compositions are useful
for the treatment of colorectal cancer, prostate cancer, brain
cancer, liver cancer, breast cancer and lung cancer. In
particular, the arylquinoline compounds and their pharma
ceutically acceptable salts and compositions are particularly
useful in the treatment of lung cancer and prostate cancer.
The Par-4 gene was first identified in 1994 in prostate
cancer cells undergoing apoptosis. This gene encodes a
pro-apoptotic protein, Prostate Apoptosis Response-4 or
Par-4, which is remarkably effective in inducing cancer cell
apoptosis and tumor regression in animal models. Par-4 does
not affect normal cells. Par-4 protein is secreted in cell
culture-conditioned medium (CM) or systemically in mice
by normal cells, and extracellular Par-4 binds to its receptor
GRP78 on the cancer cell surface and induces apoptosis.
Normal cells express low to undetectable levels of cell
surface GRP78 and are resistant to apoptosis by extracellular
Par-4.
Par-4 induces apoptosis in many types of cancer cells. For
cancer cells that may be resistant to direct apoptosis by
Par-4, overexpression of Par-4 in these cells renders them
supersensitive to a broad range of apoptotic insults, includ
ing chemotherapeutic agents, TNF, or ionizing radiation.
Applicants have also found that GRP78 levels can be
increased on the surface of diverse cancer cells to overcome
Par-4-resistance by inhibition of NF-KB activity, which is
usually elevated in most cancer cells. Therefore, the arylqui
noline compounds of the subject technology can be admin
istered either alone or in combination with a second active
ingredient such as a chemotherapeutic agent or an NF-KB
inhibitor for treating cancer or cancer metastasis.
As the baseline levels of Par-4 secreted by normal cells
are generally inadequate to cause massive apoptosis in
cancer cell cultures, secretogogues that bolster the release of
Par-4 would constitute an important therapeutic advance.
The subject technology thus relates to a new class of
"small-molecule" secretagogues, that promote the desired

6
secretion of Par-4 in vitro and in vivo by selectively target
ing an intermediate filament protein, vimentin.
The arylquinoline compounds of the present disclosure
include compounds according to Formula (I):

(I)
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wherein n is 1, 2, 3, 4, 5, or 6, for each NR1 R2 , R1 and R2
are independently H, alkyl, alkoxy, aryl, heteroaryl; Ar is
aryl, e.g., phenyl, naphthyl, and heteroaryl, e.g., pyridyl,
pyrolidyl, piperidyl, pyrimidyl, indolyl, thienyl, which can
be further substituted with halogen, amino, alkylamino,
dialkylamino, arylalkylamino, N-oxides of dialkylamino,
trialkylammonium, mercapto, alkylthio, alkanoyl, nitro,
nitrosyl, cyano, alkoxy, alkenyloxy, aryl, heteroaryl, sulfo
nyl, sulfonamide, CONR3 R4, NR3CO(R4), NR3COO(R4),
NR3CONR4R5 where R3 , R4, R5 , are independently, H,
alkyl, aryl, heteroaryl or a fluorine; X represents halogen,
e.g., a fluorine, chlorine, bromine, or iodine substituent; m is
1, 2, 3, 4, 5. This embodiment also includes pharmaceuti
cally acceptable salts of Formula (I).
In one aspect of the present disclosure, n is 1 to 3; m is
1 to 3 and X is selected from fluorine or chlorine, e.g. X is
one, two or three fluorine substituents, or X is one, two or
three chlorine substituents, or X represents at least one
fluorine and at least one chlorine on Ar. In various embodi
ments, the compound of Formula (I) includes wherein n is
at least 2 or 2 and one NR1 R2 group is at the 2 position of
the quinoline ring and another NR1 R2 group is at the 7
position of the quinoline ring; and Ar-Xm is at the 3 position
of the quinoline ring. In other embodiments, Ar is phenyl, m
is 2 and X is selected from fluoro or chloro. In further
embodiments, m is 1 and the Ar-Xm group at the 3 position
of the quinoline ring is an ortho fluoro or ortho chloro phenyl
group. In still other embodiments, the Ar-Xm group at the 3
position is a halogen substituted heteroaryl, e.g., pyridyl,
pyrolidyl, piperidyl, or pyrimidyl having one or more halogen substituents. For each of the embodiments, each of R1
and R2 of each NR1 R2 can be independently H, or a lower
alkyl.
In another aspect, the subject technology relates to com
pounds where the Ar-Xm group is located at the 3 position
of the quinoline ring and Ar is a phenyl group such as shown
in formulas (II) or (III):

60

(II)
I
--Xm
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(III)

or a pharmaceutically acceptable salt thereof; wherein Z is
O or S; and n, R 1 , R2 , X and m are as defined for the
compound of Formula (I).
In one aspect of this embodiment, the compounds of
Formula (II) and Formula (III) have n as 1, 2, or 3 and m as
1, 2, or 3, e.g., the compounds include one NR 1 R2 group at
the 2 position of the quinoline ring and another NR 1 R2 group
at the 7 position of the quinoline ring, and X is selected from
fluoro or chloro. In other embodiments, the compounds of
Formula (II) or (III) have n as 2, m as 2 and X selected from
fluoro or chloro. In still further embodiments, the com
pounds of Formula (II) or (III) have n as 2, m as 1 and X
selected as chloro or fluoro at the ortho position of the
phenyl ring. For each of the embodiments, each R 1 and R2
of each NR 1 R2 can be independently H, or a lower alkyl.
Another aspect of the subject technology includes a
biotinylated derivative or other detectably labeled alterna
tive of each of Formulas (I), (II) and (III) and their various
embodiments.
Particular arylquinoline compounds of the subject tech
nology include 3-(2-fluorophenyl)-N7,N7-dimethylquino
line-2, 7-diamine (Arylquin 1); 3-(3-fluorophenyl)-N7,N7 dimethylquinoline-2,7-diamine
(Arylquin
2);
3-(4fluorophenyl)-N7,N7-dimethylquinoline-2,7-diamine
(Arylquin 3); 7-( dimethylamino)-3-(2-fluorophenyl)quino
lin-2(1H)-one (Arylquin 4); 7-(dimethylamino)-3-(2-fluoro
phenyl)quinoline-2(1H)-thione (Arylquin 5); 3-(2-fluoro
phenyl)-N,N-dimethylquinolin-7-amine (Arylquin 6); 3-(2fluorophenyl)quinolin-2-amine (Arylquin 8); N-(2-(2-(2-(2(7-( dimethylamino)-3-(2-fluorophenyl)quinolin-2-ylthio)
acetamido)ethoxy)ethoxy)ethyl)-5-(2-oxohexahydro-l Hthieno[3,4-d]imidazol-4-yl)pentanamide
(Biotinylated
Arylquin 9).
One of these novel secretagogues, namely Arylquin-1
(FIG. 1), causes particularly robust secretion of Par-4 pro
tein from normal cells and elevates systemic levels of Par-4,
thereby providing an effective strategy for the induction of
apoptosis of circulating cancer cells as well as the inhibition
of the growth of primary and metastatic tumors.
For example, lung cancer, the leading cause of cancer
deaths in the US, is commonly associated with oncogenic
K-Ras and loss of tumor suppressor p53 function contrib
uting to therapy resistance. Lung cancer cells that express
oncogenic Ras or are deficient in p53 function are, however,
sensitive to apoptosis by the tumor suppressor protein Par-4.
Applicants have found that elevated levels of Par-4 secreted
from the normal cells in response to Arylquin-1 are adequate
to induce paracrine apoptosis of p53-wild type and p53deficient lung cancer cells as well as those expressing
oncogenic K-ras. These findings imply that secretagogues
like Arylquin-1 functionally trigger the secretion of Par-4
from normal cells to induce apoptosis of lung cancer cells.
Applicants have further found that endogenous vimentin
binds to and sequesters Par-4, and that the Arylquin-1
secretagogue functions by binding to vimentin and releasing
Par-4 for secretion.
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In the following detailed description, numerous specific
details are set forth to provide a full understanding of the
subject technology. It will be apparent, however, to one
ordinarily skilled in the art that the subject technology may
be practiced without some of these specific details. In other
instances, well-known structures and techniques have not
been shown in detail so as not to obscure the subject
technology.
To facilitate an understanding of the present subject
technology, a number of terms and phrases are defined
below:
The term "unit dose" or "dosage" refers to physically
discrete units suitable for use in a subject, each unit con
taining a predetermined-quantity of the therapeutic compo
sition calculated to produce the desired responses discussed
above in association with its administration, i.e., the appropriate route and treatment regimen. The quantity to be
administered, both according to number of treatments and
unit dose, depends on the protection or effect desired.
The term "treat" and "treatment" refer to both therapeutic
treatment and prophylactic, inhibition or preventative mea
sures, wherein the object is to inhibit, prevent or slow down
(lessen) an undesired pathological change or disorder, such
as the development or spread of cancer. For purpose of this
disclosure, beneficial or desired clinical results include, but
are not limited to, alleviation of symptoms, diminishment of
extent of disease, stabilized (i.e., not worsening) state of
disease, delay or slowing of disease progression, ameliora
tion or palliation of the disease state, and remission (whether
partial or total), whether detectable or undetectable. For
example, "treatment" can include a qualitative or quantita
tive reduction (e.g., by at least 10%, 20%, 30%, 40%, 50%,
60%, 70%, 80%, 90%, 95%, or more) in the tumor or
metastases size or reduce, inhibit, or prevent metastatic
growth. "Treatment" can also mean prolonging survival as
compared to expected survival if not receiving treatment.
Those in need of treatment include those already with the
condition or disorder as well as those prone to have the
condition or disorder or those in which the condition or
disorder is to be prevented.
The phrase "therapeutically effective amount" means an
amount of a compound of the subject technology that (i)
treats, inhibits, or prevents the particular disease, condition,
or disorder, (ii) attenuates, ameliorates, or eliminates one or
more symptoms of the particular disease, condition, or
disorder, or (iii) prevents or delays the onset of one or more
symptoms of the particular disease, condition, or disorder
described herein. In the case of cancer, the therapeutically
effective amount of the drug may be reduce the number of
cancer cells; reduce the tumor size; inhibit (i.e., slow to
some extent and preferably stop) cancer cell infiltration into
peripheral organs; inhibit (i.e., slow to some extent and
preferably prevent or stop) tumor metastasis; inhibit, to
some extent, tumor growth; and/or relieve to some extent
one or more of the symptoms associated with the cancer. To
the extent the drug may prevent growth, inhibit, and/or kill
existing cancer cells, it may be cytostatic and/or cytotoxic.
For cancer therapy, efficacy can be measured, for example,
by assessing the time to disease progression (TTP) and/or
determining the response rate (RR).
The terms "cancer" and "cancerous" refer to or describe
the physiological condition in mammals that is typically
characterized by unregulated cell growth. A "tumor" com
prises one or more cancerous cells. Examples of cancer
include, but are not limited to, carcinoma, lymphoma, blas
toma, sarcoma, and leukemia or lymphoid malignancies.
More particular examples of such cancers include squamous
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cell cancer (e.g., epithelial squamous cell cancer), lung
cancer including small-cell lung cancer, non-small cell lung
cancer ("NSCLC"), adenocarcinoma of the lung and
squamous carcinoma of the lung, cancer of the peritoneum,
hepatocellular cancer, gastric or stomach cancer including
gastrointestinal cancer, pancreatic cancer, glioblastoma, cer
vical cancer, ovarian cancer, liver cancer, bladder cancer,
hepatome, breast cancer, colon cancer, rectal cancer, col
orectal cancer, endometrial or uterine carcinoma, salivary
gland carcinoma, kidney or renal cancer, prostate cancer,
vulva! cancer, thyroid cancer, hepatic carcinoma, anal car
cinoma, penile carcinoma, as well as head and neck cancer.
The term "prodrug" as used in this application refers to a
precursor or derivative form of a compound of the disclosure
that may be less cytotoxic to cells compared to the parent
compound or drug and is capable of being enzymatically or
hydrolytically activated or converted into the more active
parent form. The prodrugs of this disclosure include, but are
not limited to, phosphate-containing prodrugs, thiophosphate-containing prodrugs, sulfate-containing prodrugs,
peptide-containing prodrugs, D-amino acid-modified prod
rugs, glycosylated prodrugs, �-lactam-containing prodrugs,
optionally substituted phenoxyacetamide-containing prod
rugs, optionally substituted phenylacetamide-containing
prodrugs, 5-fluorocytosine and other 5-fluorouridine prod
rugs which can be converted into the more active cytotoxic
free drug.
A "metabolite" is a product produced through metabolism
in the body of a specified compound or salt thereof. Metabo
lites of a compound may be identified using routine tech
niques known in the art and their activities determined using
tests such as those described herein. Such products may
result for example from the oxidation, reduction, hydrolysis,
amidation, deamidation, esterification, deesterification,
enzymatic cleavage, and the like, of the administered com
pound.
The term "alkyl" is art-recognized, and includes saturated
aliphatic groups, including straight-chain alkyl groups,
branched-chain alkyl groups, cycloalkyl (alicyclic) groups,
alkyl substituted cycloalkyl groups, and cycloalkyl substi
tuted alkyl groups. In certain embodiments, a straight chain
or branched chain alkyl has about 30 or fewer carbon atoms
in its backbone (e.g., C 1 -C30 for straight chain, C3 -C30 for
branched chain), and alternatively, about 20 or fewer. Like
wise, cycloalkyls have from about 3 to about 10 carbon
atoms in their ring structure, and alternatively about 5, 6 or
7 carbons in the ring structure. The term "alkyl" as used
herein also includes halo-substituted alkyls.
Unless the number of carbons is otherwise specified,
"lower alkyl" refers to an alkyl group, as defined above, but
having from one to about ten carbons (C 1 -C 10), e.g., from
one to about six carbon atoms (C 1 -C 6) in its backbone
structure. Likewise, "lower alkenyl" "loweralkyl, "lower
amino", "lower alkynyl", etc. have similar chain lengths.
Therapeutic Agents
Disclosed herein are arylquinoline compounds, i.e., com
pounds of Formula (I), (II) and (III), and their use in treating
cancer cells or in treating, or inhibiting metastatic cells.
Such compounds of the subject technology are Par-4 secre
tagogues, i.e., promote secretin of Par-4 from cells, which
promote apoptosis in cancer cells or metastatic cells. Such
compounds are described as "arylquins" as a general
descriptor of Par-4 secretagogues. Thus, in an embodiment,
the compounds of the subject technology are useful in
treating cancers including, but not limited to, colorectal
cancer, liver cancer, breast cancer and lung cancer.
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Synthesis
The compounds of the subject technology, including
compounds of Formula (I) to Formula (II), may be prepared
by methods disclosed herein or any other method known in
the art. One of ordinary skill in the art will know how to
modify procedures to obtain the analogs of the subject
technology. In addition, compounds may be prepared using
the methods described below and in Example 1 or modified
versions thereof.
FIG. 1 is a schematic of the general synthesis of certain
arylquinoline compounds of the subject technology. Addi
tional arylquinoline compounds of the subject technology
can be made by similar methods or known synthetic proce
dures known in the art in light of the subject technology.
The subject technology also encompasses biotinylated
derivatives of the arylquinoline compounds. Such bioti
nylated derivatives are useful in identifying the molecular
target for these agents. Compounds encompassed by For
mulas (I), (II) and (II) can be synthesized and converted to
biotinylated derivatives.
In certain embodiments of the subject technology, the
arylquinoline compounds of the disclosure, or a pharmaceu
tically acceptable salt, solvate, hydrate or prodrug thereof,
inhibit the growth or spread of cancer cells by promoting
apoptosis in them.
Metabolites of Compounds of the Disclosure
Also falling within the scope of this disclosure are the in
vivo metabolic products of Formulas (I) to (II) described
herein. Such products may result for example from the
oxidation, reduction, hydrolysis, amidation, deamidation,
esterification, deesterification, enzymatic cleavage, and the
like, of the administered compound.
Accordingly, the disclosure includes metabolites of com
pounds of Formulas (I) to (II), including compounds pro
duced by a process comprising contacting a compound of
this disclosure with a mammal for a period of time sufficient
to yield a metabolic product thereof.
Metabolite products typically are identified by preparing
a detectably labeled, for example a radiolabeled (e.g., C or
H isotope) compound of the disclosure, administering it
parenterally in a detectable dose (e.g., greater than about 0.5
mg/kg) to an animal such as rat, mouse, guinea pig, monkey,
or to man, allowing sufficient time for metabolism to occur
(typically about 30 seconds to 30 hours) and isolating its
conversion products from the urine, blood or other biological samples. These products are easily isolated since they are
detectably labeled (others are isolated by the use of anti
bodies capable of binding epitopes surviving in the metabo
lite). The metabolite structures are determined in conven
tional fashion, e.g., by MS, LC/MS or NMR analysis. In
general, analysis of metabolites is done in the same way as
conventional drug metabolism studies, which are well
known to those skilled in the art. The metabolite products,
so long as they are not otherwise found in vivo, are useful
in diagnostic assays for therapeutic dosing of the compounds
of the disclosure.
Prodrugs of the Compounds of the Disclosure
In addition to compounds of the subject technology, the
disclosure also includes pharmaceutically acceptable prod
rugs of such compounds. Prodrugs include compounds
wherein an amino acid residue, or a polypeptide chain of two
or more (e.g., two, three or four) amino acid residues, is
covalently joined through an amide or ester bond to a free
amino, hydroxy or carboxylic acid group of a compound of
the subject technology. The amino acid residues include but
are not limited to the 20 naturally occurring amino acids
commonly designated by three letter symbols and also
includes phosphoserine, phosphothreonine, phosphotyro-
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sine, 4-hydroxyproline, hydroxyzine, demosine, isodem
osine, gamma-carboxyglutamate, hippuric acid, octahy
droindole-2-carboxylic
acid,
statine,
1,2,3,4tetrahydroisoquinoline-3-carboxylic acid, penicillamine,
omithine, 3-methylhistidine, norvaline, beta-alanine,
gamma-aminobutyric acid, citrulline, homocysteine, homo
serine, methyl-alanine, para-benzoylphenylalanine, phenyl
glycine, propargylglycine, sarcosine, methionine sulfone
and tert-butylglycine.
For additional examples of prodrug derivatives, see, for
example, a) Design of Prodrugs, edited by H. Bundgaard,
(Elsevier, 1985) and Methods in Enzymology, Vol. 42, p.
309-396, edited by K. Widder, et al. (Academic Press, 1985);
b) A Textbook of Drug Design and Development, edited by
Krogsgaard-Larsen and H. Bundgaard, Chapter 5 "Design
and Application of Prodrugs," by H. Bundgaard p. 113-191
(1991); c) H. Bundgaard, Advanced Drug Delivery Reviews,
8:1-38 (1992); d) H. Bundgaard, et al., Journal of Pharma
ceutical Sciences, 77:285 (1988); and e) N. Kakeya, et al.,
Chem. Phann. Bull., 32:692 (1984), each of which is spe
cifically incorporated herein by reference.
Pharmaceutical Compositions
The subject technology also encompasses pharmaceutical
compositions comprising at least one arylquinoline com
pounds, e.g., one or more compounds of Formula (I), (II),
and/or Formula (III) and/or one or more pharmaceutically
acceptable salts thereof, in combination with a pharmaceu
tical carrier or excipient. In one embodiment of the subject
technology, the pharmaceutical compositions comprise an
effective amount of at least one such compound. In another
embodiment, the pharmaceutical composition comprises
one or more compounds of Formula (III), e.g., Arylquin-1,
and a pharmaceutically acceptable carrier.
While it may be possible for compounds of the subject
technology to be administered as the raw chemical, it is
preferable to present them as a pharmaceutical composition.
According to a further aspect, the subject technology pro
vides a pharmaceutical composition comprising a compound
or mixture of compounds of Formula (I) to Formula (II) or
a pharmaceutically acceptable salt, solvate, hydrate, prodrug
or metabolite thereof, together with one or more pharma
ceutical carrier, excipient or additive and optionally one or
more other therapeutic ingredients. The carrier(s) must be
"acceptable" in the sense of being compatible with the other
ingredients of the formulation and not deleterious to the
recipient thereof. The term "pharmaceutically acceptable
carrier" includes vehicles and diluents.
To prepare the pharmaceutical compositions, a therapeu
tically effective amount of one or more of the arylquinoline
compounds according to the subject technology may be
intimately admixed with a pharmaceutically acceptable car
rier according to conventional pharmaceutical compounding
techniques to produce a dose. A carrier may take a wide
variety of forms depending on the form of preparation
desired for administration, e.g., oral, topical or parenteral,
including gels, creams ointments, lotions and time released
implantable preparations, among numerous others. In pre
paring pharmaceutical compositions in oral dosage form,
any of the usual pharmaceutical media may be used. Thus,
for liquid oral preparations such as suspensions, elixirs and
solutions, suitable carriers and additives including water,
glycols, oils, alcohols, flavoring agents, preservatives, col
oring agents and the like may be used. For solid oral
preparations such as powders, tablets, capsules, and for solid
preparations such as suppositories, suitable carriers and
additives including starches, sugar carriers, such as dextrose,
mannitol, lactose and related carriers, diluents, granulating
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agents, lubricants, binders, disintegrating agents and the like
may be used. If desired, the tablets or capsules may be
enteric-coated or sustained release by standard techniques.
In one embodiment, the compositions are prepared with
carriers that will protect the active compound(s) against
rapid elimination from the body, such as a controlled release
formulation, including implants and microencapsulated
delivery systems. Biodegradable, biocompatible polymers
can be used, such as ethylene vinyl acetate, polyanhydrides,
polyglycolic acid, collagen, polyorthoesters, and polylactic
acid. Methods for preparation of such formulations will be
apparent to those skilled in the art.
The pharmaceutically acceptable carrier may take a wide
variety of forms, depending on the route desired for admin
istration, for example, oral or parenteral (including intrave
nous). Carriers such as starches, sugars, microcrystalline
cellulose, diluents, granulating agents, lubricants, binders
and disintegrating agents may be used in the case of oral
solid preparations such as powders, capsules and caplets,
with the solid oral preparation being preferred over the
liquid preparations. Preferred solid oral preparations are
tablets or capsules, because of their ease of administration.
If desired, tablets may be coated by standard aqueous or
nonaqueous techniques. Oral and parenteral sustained
release dosage forms may also be used.
Liposomal suspensions may also be pharmaceutically
acceptable carriers. These may be prepared according to
methods known to those skilled in the art. For example,
liposomal formulations may be prepared by dissolving
appropriate lipid(s) in an inorganic solvent that is then
evaporated, leaving behind a thin film of dried lipid on the
surface of the container. An aqueous solution of the active
compound is then introduced into the container. The container is then swirled by hand to free lipid material from the
sides of the container and to disperse lipid aggregates,
thereby forming the liposomal suspension. Other methods of
preparation well known by those of ordinary skill may also
be used in this aspect of the subject technology.
In an embodiment, the composition of the subject technology enables sustained, continuous delivery of a com
pound of Formula (I) to Formula (II) or a pharmaceutically
acceptable salt, solvate, hydrate, prodrug or metabolite
thereof, to tissues adjacent to or distant from an administration site. The biologically-active agent is capable of
providing a local or systemic biological, physiological or
therapeutic effect. For example, a compound of Formula (I)
to Formula (II) or a pharmaceutically acceptable salt, sol
vate, hydrate, prodrug or metabolite thereof, may act to kill
cancer cells, or cancer stem cells or to control or suppress
tumor growth or metastasis, among other functions.
Formulations and Dosages for Administration
Pharmaceutical formulations based upon arylquinoline
compounds of the subject technology comprise at least one
of the compounds of Formula (I) to Formula (III) or a
pharmaceutically acceptable salt, solvate, hydrate, prodrug
or metabolite thereof, in a therapeutically effective amount
for treating neoplasia, cancer and other diseases and condi
tions that may benefit from induced Par-4 secretion, optionally in combination with a pharmaceutically acceptable
additive, carrier and/or excipient. One of ordinary skill in the
art will recognize that a therapeutically effective amount of
one of more compounds according to the subject technology
will vary with the condition to be treated, its severity, the
treatment regimen to be employed, the pharmacokinetics of
the agent used, as well as the patient (animal or human)
treated.
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Exemplary formulations are well known to those skilled
in the art, and general methods for preparing them are found
in any standard pharmacy school textbook, for example,
Remington: THE SCIENCE AND PRACTICE OF PHAR
MACY, 21st Ed., Lippincott. The formulations of the subject
technology may conveniently be presented in unit dosage
form and may be prepared by any of the methods well
known in the art of pharmacy. All methods include the step
of bringing into association a compound or a pharmaceuti
cally acceptable salt or solvate thereof ("active ingredient")
with the carrier which constitutes one or more accessory
ingredients. In general, the formulations are prepared by
uniformly and intimately bringing into association the active
ingredient with liquid carriers or finely divided solid carriers
or both and then, if necessary, shaping the product into the
desired formulation. Oral formulations are well known to
those skilled in the art, and general methods for preparing
them are found in any standard pharmacy school textbook,
for example, Remington: THE SCIENCE AND PRACTICE
OF PHARMACY, 21st Ed., the entire disclosure of which is
incorporated herein by reference.
The concentration of active compound of the subject
technology, i.e., at least one of the compounds of Formula (I)
to Formula (III) or a pharmaceutically acceptable salt,
solvate, hydrate, prodrug or metabolite thereof, in the drug
composition will depend on absorption, distribution, inacti
vation, and excretion rates of the drug as well as other
factors known to those of skill in the art. It is to be noted that
dosage values will also vary with the severity of the condi
tion to be alleviated. The composition may be administered
at once, or may be divided into a number of smaller doses
to be administered at varying intervals of time.
Oral compositions will generally include an inert diluent
or an edible carrier. They may be enclosed in gelatin
capsules or compressed into tablets. For the purpose of oral
therapeutic administration, the active compound or its pro
drug derivative can be incorporated with excipients and used
in the form of tablets, troches, or capsules. Pharmaceutically
compatible binding agents, and/or adjuvant materials can be
included as part of the composition.
The tablets, pills, capsules, troches and the like can
contain any of the following non-limiting ingredients, or
compounds of a similar nature: a binder such as microcrys
talline cellulose, gum tragacanth or gelatin; an excipient
such as starch or lactose, a dispersing agent such as alginic
acid or corn starch; a lubricant such as magnesium stearate;
a glidant such as colloidal silicon dioxide; a sweetening
agent such as sucrose or saccharin; or a flavoring agent such
as peppermint, methyl salicylate, or fruit flavoring. When
the dosage unit form is a capsule, it can contain, in addition
to any of the above, a liquid carrier such as fatty oil. In
addition, dosage unit forms can contain various other mate
rials which modify the physical form of the dosage unit, for
example, coatings of sugar, shellac, or enteric agents.
The tablets, for example, may optionally be coated or
scored and may be formulated so as to provide sustained,
delayed or controlled release of the active ingredient therein.
Oral and parenteral sustained release drug delivery systems
are well known to those skilled in the art, and general
methods of achieving sustained release of orally or parenterally administered drugs are found, for example, in Rem
ington: The Science and Practice of Pharmacy, 21st Ed.
The active compound may also be administered as a
component of an elixir, suspension, syrup, wafer or the like.
Syrup may contain, in addition to the active compounds,
sucrose or fructose as a sweetening agent and certain pre
servatives, dyes and colorings and flavors.
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In certain embodiments of the subject technology, the
arylquinoline compounds are formulated as admixture with
a pharmaceutically acceptable carrier, excipient or additive.
In certain pharmaceutical dosage forms, the pro-drug form
of the compounds may be preferred. One of ordinary skill in
the art will recognize how to readily modify the present
compounds to pro-drug forms to facilitate delivery of active
compounds to a targeted site within the host organism or
patient. The mutineer also will take advantage of favorable
pharmacokinetic parameters of the pro-drug forms, where
applicable, in delivering the present compounds to a targeted
site within the host organism or patient to maximize the
intended effect of the compound.
Pharmaceutical compositions containing any of the compounds of Formula (I) to Formula (III) or a pharmaceutically
acceptable salt, solvate, hydrate, prodrug or metabolite
thereof, may be conveniently presented in unit dosage form
and prepared by any of the methods well known in the art of
pharmacy. Preferred unit dosage formulations are those
containing an effective dose, or an appropriate fraction
thereof, of the active ingredient, or a pharmaceutically
acceptable salt thereof. The magnitude of a prophylactic or
therapeutic dose typically varies with the nature and severity
of the condition to be treated and the route of administration.
The dose, and perhaps the dose frequency, will also vary
according to the age, body weight and response of the
individual patient. In general, the total daily dose (in single
or divided doses) ranges from about 0.0001 mg per day to
about 2 mg per day, or about 0.1 mg per day to about 100
mg per day, or about 10 mg per day to about 1000 mg per
day, or from about 100 mg per day to about 10000 mg per
day, or from about 5 mg per day to about 100 mg per day,
to about 50 mg per day or to about 250 mg per day. In some
embodiments, the total daily dose may range from about 1
mg per day to about 50 mg per day, or about 10 mg per day
to about 500 mg per day. It is further recommended that
children, patients over 65 years old, and those with impaired
renal or hepatic function, initially receive low doses, and
that the dosage be titrated based on individual responses
and/or blood levels. It may be necessary to use dosages
outside these ranges in some cases, as will be apparent to
those in the art. Further, it is noted that the clinician or
treating physician knows how and when to interrupt, adjust
or terminate therapy in conjunction with individual patient's
response.
Alternatively, the maximum safe starting dose of the
compounds of the subject technology for use in initial
clinical trials in adults may be determined by following, for
example, the FDA guidelines for estimating maximum safe
dosage. These guidelines provide guidance for using the
dosages used in animal studies to extrapolate safe dosage for
use in human trials. See Guidance for Industry, Estimating
the Maximum Safe Starting Dose in Initial Clinical Trials for
Therapeutics in Adult Healthy Volunteers, Food and Drug
Administration, Center for Drug Evaluation and Research
(CDER), July 2005.
In an embodiment, the amount of compound included
within therapeutically effective formulations of the subject
technology is an effective amount for treating cancer or
cancer metastasis by promoting apoptosis in the cancer cells.
In general, a therapeutically effective amount of the present
preferred compound in dosage form usually ranges from
slightly less than about 0.0001 mg/kg to about 0.003 mg/kg
or about 0.0025 mg/kg to about 2.5 g/kg, and in certain
embodiments about 0.025 mg/kg to about 5 mg/kg or about
0.25 mg/kg to about 100 mg/kg or about 2.5 mg/kg to about
250 mg/kg or about 25 mg/kg to about 500 mg/kg or
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considerably more, depending upon the compound used, the
condition being treated and the route of administration,
although exceptions to this dosage range may be contem
plated by the subject technology. In some embodiments,
arylquinoline compounds of the subject technology are
administered in amounts ranging from about 0.0001 mg/kg
to about 1000 mg/kg.
The active compound of the subject technology, i.e., at
least one of the compounds of Formula (I), (II), or (II) or a
pharmaceutically acceptable salt, solvate, hydrate, prodrug
or metabolite thereof, is included in the pharmaceutically
acceptable carrier or diluent in an amount sufficient to
deliver to a patient a therapeutically effective amount for the
desired indication, without causing serious toxic effects in
the patient treated.
In certain embodiments, the active compound is conve
niently administered in any suitable unit dosage form,
including but not limited to one containing 1 to 3000 mg,
preferably 5 to 500 mg of active ingredient per unit dosage
form. An oral dosage of 10-250 mg is usually convenient.
The actual dosage amount of a composition of the subject
technology administered to a patient or subject can be
determined by physical and physiological factors such as
body weight, severity of condition, the type of disease being
treated, previous or concurrent therapeutic interventions,
idiopathy of the patient and on the route of administration.
The practitioner responsible for administration will, in any
event, determine the concentration of active ingredient(s) in
a composition and appropriate dose(s) for the individual
subject.
In certain embodiments, pharmaceutical compositions
may comprise, for example, at least about 0.1% of an active
compound, i.e., at least one of the compounds of Formula
(I), (II), (III) or a pharmaceutically acceptable salt, solvate,
hydrate, prodrug or metabolite thereof. In other embodiments, the active compound may comprise between about
1% to about 75% of the weight of the unit, or between about
5% to about 50%, for example, and any range derivable
therein. In other non-limiting examples, a dose may also
comprise about 0.001 microgram/kg/body weight to about 5
microgram/kg/body weight, or about 1 microgram/kg/body
weight to about 50 microgram/kg/body weight, or about 20
milligram/kg/body weight to about 150 milligram/kg/body
weight, or about 100 milligram/kg/body weight to about 300
milligram/kg/body weight, or about 200 milligram/kg/body
weight to about 1000 milligram/kg/body weight or more per
administration, and any range derivable therein. In non
limiting examples of a derivable range from the numbers
listed herein, a range of about 1 microgram/kg/body weight
to about 50 milligram/kg/body weight, or from about 20
microgram/kg/body weight to about 500 milligram/kg/body
weight, etc., can be administered.
Route of Administration
In accordance with the methods of the subject technology,
the described arylquinoline compounds of the subject technology or a pharmaceutically acceptable salt, solvate,
hydrate or prodrug thereof, may be administered to a subject
in a variety of forms depending on the selected route of
administration, as will be understood by those skilled in the
art. The active compound of the disclosure may be administered, for example, by oral, parenteral (including subcuta
neous, intradermal, intramuscular, intravenous, intraperito
neal, intratumoral and intraarticular, intratumoral,
transepithelial, nasal, intrapulmonary, intrathecal), buccal,
sublingual, nasal, rectal, topical (including dermal, buccal,
sublingual and intraocular), or transdermal administration as
well as those for administration by inhalation. Parenteral
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administration includes intravenous, intraperitoneal, subcu
taneous, intramuscular, intratumoral, transepithelial, nasal,
intrapulmonary, intrathecal, rectal and topical modes of
administration. Parenteral administration may be by con
tinuous infusion over a selected period of time
Alternatively, the compounds of this disclosure may be
incorporated into formulations for any route of administra
tion including for example, oral, topical and parenteral
including intravenous, intramuscular, eye or ocular, intrap
eritoneal, intrabuccal, transdermal and in suppository form.
Of course, one of ordinary skill in the art may modify the
formulations within the teachings of the specification to
provide numerous formulations for a particular route of
administration without rendering the pharmaceutical compositions unstable or compromising their therapeutic activ
ity. It is also well within the mutineer's skill to modify the
route of administration and dosage regimen of a particular
compound in order to manage the pharmacokinetics of the
present compounds for maximum beneficial effect to the
patient.
Methods of Treatment
In an embodiment, the subject technology is directed to
methods for treating cancer or treating and/or inhibiting
cancer metastasis in a subject comprising administering to
the subject an effective amount of a compound or compo
sition of one or more compounds of Formula (I), (II), and/or
Formula (III) and/or one or more pharmaceutically accept
able salt, solvate, hydrate, prodrug or metabolite thereof.
For example, the subject technology contemplates methods of treating various cancers and complications thereof.
More particularly, the subject technology relates to methods
for inhibiting the growth of benign and malignant cancer,
including a malignant tumor or cancer comprising exposing
the tumor to an inhibitory or therapeutically effective
amount or concentration of at least one arylquinoline com
pound or pharmaceutically acceptable salts or pharmaceutically acceptable composition thereof. Treatment of internal
malignancies such as eye or ocular cancer, rectal cancer,
colon cancer, cervical cancer, prostate cancer, breast cancer,
liver cancer and bladder cancer, and age-related cancer
among numerous others are contemplated by the subject
technology.
Accordingly, the compounds and/or compositions of the
subject technology are useful for treating animals, and in
particular, mammals, including humans, as patients. Thus,
humans and other animals, and in particular, mammals,
suffering from cancer can be treated by administering to the
patient an effective amount of one or more of the arylqui
noline compounds according to the subject technology, or its
derivative or a pharmaceutically acceptable salt thereof,
optionally in a pharmaceutically acceptable carrier or
diluent, either alone, or in combination with other known
pharmaceutical agents (depending upon the disease to be
treated). Treatment according to the subject technology can
also be by administration of the compounds and/or compo
sitions of the subject technology in conjunction with other
conventional cancer therapies, such as radiation treatment or
surgery or administration of other anti-cancer agents.
In certain embodiments, the subject technology can find
application in the treatment of any disease for which deliv
ery of a therapeutic arylquinoline compound or a pharma
ceutically acceptable salt, solvate, hydrate, prodrug or
metabolite thereof to a cell or tissue of a subject is believed
to be of therapeutic benefit. Examples of such diseases
include hyperproliferative diseases and quiescent malignant
diseases. In particular embodiments, the disease is a hyperproliferative disease, such as cancer of solid tissues or blood
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cells. Quiescent malignant diseases that can be treated by an
arylquinoline compound of the subject technology or a
pharmaceutically acceptable salt, solvate, hydrate, prodrug
or metabolite thereof include, for example, chronic lympho
cytic leukemia.
For example, a compound or composition of an arylqui
noline compound of the subject technology or a pharma
ceutically acceptable salt, solvate, hydrate, prodrug or
metabolite thereof can be administered to treat a hyperpro
liferative disease. The hyperproliferative disease may be
cancer, leiomyomas, adenomas, lipomas, hemangiomas,
fibromas, pre-neoplastic lesions (such as adenomatous
hyperplasia and prostatic intraepithelial neoplasia), carci
noma in situ, oral hairy leukoplakia, or psoriasis, for
example.
The cancer may be a solid tumor, metastatic cancer, or
non-metastatic cancer. In certain embodiments, the cancer
may originate in the bladder, blood, bone, bone marrow,
brain, breast, colon, esophagus, duodenum, small intestine,
large intestine, colon, rectum, anus, gum, head, kidney, liver,
lung, nasopharynx, neck, ovary, prostate, skin, stomach,
testis, tongue, or uterus. In certain embodiments, the cancer
is ovarian cancer. In particular aspects, the cancer may be a
chemo-resistant cancer, i.e., refractive forms of cancer, such
as taxane-resistant or cisplatin resistant cancer.
In another aspect, the subject technology provides a
method for promoting secretin of Par-4 in a cell by contact
ing the cell with an effective amount of an arylquinoline
compound of the subject technology. In another aspect, there
is provided a method for promoting apoptosis in a cancer
cell by contacting the cell with an effective amount of an
arylquinoline compound of the subject technology.
Combination Therapy
The active compounds of the subject technology, i.e., one
or more compounds of Formula (I) to (III) and/or one or
more pharmaceutically acceptable salt, solvate, hydrate,
prodrug or metabolite thereof can also be mixed with other
active materials that do not impair the desired action, or with
materials that supplement the desired action, such as che
motherapeutic agents, NF-KB inhibitors, other anticancer
agents, and in certain instances depending upon the desired
therapy or target, antibiotics, antifungals, antinflammatories,
antiviral compounds or other agents having a distinct phar
macological effect.
The methods and compositions of the subject technology
further provide combination therapies which can enhance
the therapeutic or protective effect of the compounds of the
subject technology, and/or increase the therapeutic effect of
another anti-cancer. Therapeutic and prophylactic methods
and compositions can be provided in a combined amount
effective to achieve the desired effect, such as the killing of
a cancer cell and/or the inhibition of cancer metastasis. This
process may involve contacting the cells with, for example,
a therapeutic nucleic acid, such as a chemotherapeutic agent
or an inhibitor of gene expression, as a second therapy. A
tissue, tumor, or cell can be contacted with the compounds
or compositions of the subject technology and one or more
additional anti-cancer treatment. For example, an additional
anticancer treatment may include a chemotherapeutic agent,
an NF-KB inhibitor, an anti-hormonal agent, radiotherapy,
surgical therapy, or immunotherapy.
Examples of chemotherapeutic agents include alkylating
agents such as thiotepa and cyclosphosphamide; alkyl sul
fonates such as busulfan, improsulfan and piposulfan; aziri
dines such as benzodopa, carboquone, meturedopa, and
uredopa; ethylenimines and methylamelamines including
altretamine, triethylenemelamine, trietylenephosphoramide,
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triethiylenethiophosphoramide and trimethylolomelamine;
acetogenins (especially bullatacin and bullatacinone); a
camptothecin (including the synthetic analogue topotecan);
bryostatin; callystatin; CC-1065 (including its adozelesin,
carzelesin and bizelesin synthetic analogues); cryptophycins
(particularly cryptophycin 1 and cryptophycin 8); dolastatin;
duocarmycin (including the synthetic analogues, KW-2189
and CBI-TMI); eleutherobin; pancratistatin; a sarcodictyin;
spongistatin; nitrogen mustards such as chlorambucil, chlo
maphazine, cholophosphamide, estramustine, ifosfamide,
mechlorethamine, mechlorethamine oxide hydrochloride,
melphalan, novembichin, phenesterine, prednimustine, tro
fosfamide, uracil mustard; nitrosureas such as carmustine,
chlorozotocin, fotemustine, lomustine, nimustine, and raninmustine; antibiotics such as the enediyne antibiotics (e.g.,
calicheamicin, especially calicheamicin ganimall and cali
cheamicin omegall; dynemicin, including dynemicin A;
bisphosphonates, such as clodronate; an esperamicin; as
well as neocarzinostatin chromophore and related chro
moprotein enediyne antiobiotic chromophores, aclacino
mysins, actinomycin, authramycin, azaserine, bleomycins,
cactinomycin, carabicin, carminomycin, carzinophilin,
chromomycinis, dactinomycin, daunorubicin, detorubicin,
6-diazo-5-oxo-L-norleucine, doxorubicin (including morpholino-doxorubicin, cyanomorpholino-doxorubicin, 2-pyr
rolino-doxorubicin and deoxy doxorubicin), epirubicin, eso
rubicin, idarubicin, marcellomycin, mitomycins such as
mitomycin C, mycophenolic acid, nogalamycin, olivomycins, peplomycin, potfiromycin, puromycin, quelamycin,
rodorubicin, streptonigrin, streptozocin, tubercidin, uben
imex, zinostatin, zorubicin; anti-metabolites such as methotrexate and 5-fluorouracil (5-FU); folic acid analogues such
as denopterin, methotrexate, pteropterin, trimetrexate;
purine analogues such as fludarabine, 6-mercaptopurine,
thiamiprine, thioguanine; pyrimidine analogues such as
ancitabine, azacitidine, 6-azauridine, carmofur, cytarabine,
dideoxyuridine, doxifluridine, enocitabine, floxuridine;
androgens such as calusterone, dromostanolone propionate,
epitiostanol, mepitiostane, testolactone; anti-adrenals such
as aminoglutethimide, mitotane, trilostane; folic acid replen
isher such as frolinic acid; aceglatone; aldophosphamide
glycoside; aminolevulinic acid; eniluracil; amsacrine;
bestrabucil; bisantrene; edatraxate; defofamine; demecol
cine; diaziquone; elformithine; elliptinium acetate; an epoth
ilone; etoglucid; gallium nitrate; hydroxyurea; lentinan;
lonidainine; maytansinoids such as maytansine and ansamitocins; mitoguazone; mitoxantrone; mopidanmol; nitraerine;
pentostatin; phenamet; pirarubicin; losoxantrone; podoph
yllinic acid; 2-ethylhydrazide; procarbazine; PSK polysac
charide complex); razoxane; rhizoxin; sizofiran; spiroger
manium;
tenuazonic
acid;
triaziquone;
2,2',2"trichlorotriethylamine; trichothecenes (especially T-2 toxin,
verracurin A, roridin A and anguidine); urethan; vindesine;
dacarbazine; mannomustine; mitobronitol; mitolactol; pipobroman; gacytosine; arabinoside ("Ara-C"); cyclophosph
amide; thiotepa; taxoids, e.g., paclitaxel and doxetaxel;
chlorambucil; gemcitabine; 6-thioguanine; mercaptopurine;
methotrexate; platinum coordination complexes such as
cisplatin, oxaliplatin and carboplatin; vinblastine; platinum;
etoposide (VP-16); ifosfamide; mitoxantrone; vincristine;
vinorelbine; novantrone; teniposide; edatrexate; daunomy
cin; aminopterin; xeloda; ibandronate; irinotecan (e.g.,
CPT-I 1); topoisomerase inhibitor RFS 2000; difluorometl
hylornithine (DMFO); retinoids such as retinoic acid;
capecitabine; cisplatin (CDDP), carboplatin, procarbazine,
mechlorethamine, cyclophosphamide, camptothecin, ifosf
amide, melphalan, chlorambucil, busulfan, nitrosurea, dac-
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tinomycin, daunorubicin, doxorubicin, bleomycin, plicomy
cin, mitomycin, etoposide (VP 16), tamoxifen, raloxifene,
estrogen receptor binding agents, taxol, paclitaxel, doc
etaxel, gemcitabien, navelbine, famesyl-protein tansferase
inhibitors, transplatinum, 5-fluorouracil, vincristine, vin
blastine and methotrexate and pharmaceutically acceptable
salts, acids or derivatives of any of the above.
Examples of nf-Kb inhibitors include 9-methylstreptimi
done, n-stearoyl phytosphingosine, 2-(1,8-naphthyridin-2yl)-phenol, 5-aminosalicylic acid, cape (caffeic acid phen
ethylester), diethylmaleate, ethyl 3,4-dihydroxycinnamate,
helenalin, nf-Kb activation inhibitor ii, nfKb activation
inhibitor iii, glucocorticoid receptor modulator, cpda, aspi
rin, ppm-18, pyrrolidinedithiocarbamic acid ammonium
salt, rocaglamide, sodium salicylate, andrographolide, (±)4hydroxynon-2-enal, ps-1145 dihydrochloride, pioglitazone,
sulindac sulfide, isohelenin, diethyldithiocarbamic acid
sodium salt trihydrate, curcumin (synthetic), trichodion
(which can be purchased, e.g., from Santa Cruz Biothech
nology, Inc. Dallas, Tex.).
Also included in the formulations may be anti-hormonal
agents that act to regulate or inhibit hormone action on
tumors such as anti-estrogens and selective estrogen receptor modulators (SERMs), including, for example, tamoxifen,
raloxifene, droloxifene, A-hydroxytamoxifen, trioxifene,
keoxifene, LYI 17018, onapristone, and toremifene; aro
matase inhibitors that inhibit the enzyme aromatase, which
regulates estrogen production in the adrenal glands, such as,
for example, 4(5)-imidazoles, aminoglutethimide, megestrol
acetate, exemestane, formestanie, fadrozole, vorozole, letrozole, and anastrozole; and anti-androgens such as flutamide,
nilutamide, bicalutamide, leuprolide, and goserelin; as well
as troxacitabine (a 1,3-dioxolane nucleoside cytosine ana
logue); antisense oligonucleotides, particularly those which
inhibit expression of genes in signaling pathways implicated
in abherant cell proliferation, such as, for example, PKC
alpha, Ralf and H-Ras; ribozymes such as a VEGF expres
sion inhibitor and a HER2 expression inhibitor; vaccines
such as gene therapy vaccines and pharmaceutically accept
able salts, acids or derivatives of any of the above.
In an embodiment, a therapeutic formulation or compo
sition set forth herein, which comprises one or more com
pounds of Formula (I) to Formula (III) and/or one or more
pharmaceutically acceptable salt, solvate, hydrate, prodrug
or metabolite thereof, may be administered before, during,
after or in various combinations relative to a second anticancer treatment. The administrations may be in intervals
ranging from concurrently to minutes to days to weeks. In
embodiments where the arylquinoline containing composi
tion is provided to a patient separately from an additional
anti-cancer agent, one would generally ensure that a signifi
cant period of time did not expire between the time of each
delivery, such that the two agents would still be able to exert
an advantageously combined effect on the patient. In such
instances, it is contemplated that one may provide a patient
with the inhibitor of gene expression therapy and the anti
cancer therapy within about 12 to 24 or 72 h of each other
and, more preferably, within about 6-12 h of each other. In
some situations it may be desirable to extend the time period
for treatment si gnificantly where several days (2, 3, 4, 5, 6
or 7) to several weeks (1, 2, 3, 4, 5, 6, 7 or 8) lapse between
respective administrations.
Within a single day (24-hour period), the patient may be
given one or multiple administrations of the agent(s). More
over, after a course of treatment, it is contemplated that there
is a period of time at which no anti-cancer treatment is
administered. This time period may last 1, 2, 3, 4, 5, 6, 7
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days, and/or 1, 2, 3, 4, 5 weeks, and/or 1, 2, 3, 4, 5, 6, 7, 8,
9, 10, 11, 12 months or more, depending on the condition of
the patient, such as their prognosis, strength, health, etc.
Administration of any compound or therapy of the subject
technology to a patient will follow general protocols for the
administration of such compounds, taking into account the
toxicity, if any, of the agents. Therefore, in some embodi
ments there is a step of monitoring toxicity that is attribut
able to combination therapy. It is expected that the treatment
cycles would be repeated as necessary. It also is contem
plated that various standard therapies, as well as radiation
and surgical intervention, may be applied in combination
with the described therapy.
In specific aspects, it is contemplated that a standard
therapy will include chemotherapy, radiotherapy, immuno
therapy, surgical therapy or gene therapy and may be
employed in combination with the combination therapy
described herein.
Articles of Manufacture
In another embodiment of the disclosure, an article of
manufacture, or "kit", containing materials useful for the
treatment of the diseases and disorders described above is
provided. In one embodiment, the kit comprises a container
comprising at least one compound of Formula (I)-(III),
and/or one or more pharmaceutically acceptable salt, solvate, hydrate, prodrug or metabolite thereof.
The kit may further comprise a label or package-insert on
or associated with the container. The term "package insert"
is used to refer to instructions customarily included in
commercial packages of therapeutic products, that contain
information about the indications, usage, dosage, adminis
tration, contraindications and/or warnings concerning the
use of such therapeutic products. Suitable containers
include, for example, bottles, vials, syringes, blister pack,
etc. The container may be formed from a variety of materials
such as glass or plastic. The container may hold a compound
of Formula (I)-(III) or a formulation thereof which is effective for treating the condition and may have a sterile access
port (for example, the container may be an intravenous
solution bag or a vial having a stopper pierceable by a
hypodermic injection needle). At least one active agent in
the composition is a compound of Formula (I)-(III). The
label or package insert indicates that the composition is used
for treating the condition of choice, such as cancer.
In an embodiment, the kit includes two separate pharma
ceutical compositions: one containing a compound of the
subject technology, and a second pharmaceutical compound.
In another embodiment, an assay or diagnostic kit includes
a labeled compound of the subject technology and one or
more reagents necessary for detecting the labeled compound
upon binding to its target in-vivo or in-vitro. In a related
embodiment, the kit includes a package insert that describes
the steps necessary for carrying out the detection assay.
In another embodiment, a kit of the disclosure further
comprises a needle or syringe, preferably packaged in sterile
form, for injecting the composition, and/or a packaged
alcohol pad. Instructions are optionally included for administration of arylquinoline compounds by a clinician or by the
patient.
Diagnostic Methods and Diagnostic Probes
Another aspect of the subject technology provides com
pounds having general formulas (I)-(III) with a linker moiety (hydrophobic linkers, hydrophilic linkers, photo-cleav
able linkers, redox reaction-cleavable linkers), wherein the
linker moiety is covalently bonded to a label molecule (a
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label could be a fluorophor, biotin, different polymer beads
and different reactive groups). An exemplary biotinylated
analog is depicted in FIG. 1.
The compounds of the subject technology when bioti
nylated provide suitable means for non-radioactive detection
of target molecules that may play a role in apoptosis
induction in cells. Therefore, another aspect of the subject
technology relates to the use of biotinylated arylquinoline
compounds as a diagnostic reagent for detecting or moni
toring the presence or levels of vimentin in a complex
protein sample. A complex protein sample contains multiple
proteins, and may additionally contain other contaminants.
Non-limiting examples of a complex protein sample include
tumor tissues, biopsy, serum and cell extracts.
In one embodiment, the subject technology relates to a
method of detecting, monitoring or analyzing the levels of
vimentin in a complex protein sample, said method com
prising adding a labeled compound of Formula (I)-(III) to
said complex protein mixture under conditions whereby said
labeled compound covalently conjugates to vimentin; isolating the conjugated vimentin by a suitable affinity-based
separation method, removing unbound proteins, detecting
the level of vimentin following the separation. In a related
embodiment, the detection can be accomplished by measur
ing a fluorescence signal emitted from the compound of
Formula (I)-(III). In another related embodiment, the detec
tion can be accomplished by measuring a fluorescence signal
emitted from a label bound via a linker to the compound of
Formula (I)-(III). The detection step can also be accom
plished using various analytical procedures that known to
the artisan for separating and analyzing complex protein
mixtures. These analytical procedures include chromato
graphic methods such as HPLC, FPLC, ion exchange, size
exclusion, mass spectrometry, and the like.
The linker moiety that can be used to attach a detectable
label to the compounds of the subject technology can be any
of the linkers shown in FIG. 1. Alternatively, the linker
moiety comprises a repeating alkyleneoxy structure (poly
ethylene glycols, or "PEG"). Thus, one of skill in the art can
select the linker moiety of the compounds of the subject
technology in order to provide additional specificity of them
for vimentin.
In an embodiment, it is desirable to have a detectable label
associated with a compound of the subject technology to
allow the compound-vimentin complex to be captured and
washed free of other components of the reaction mixture.
The label will generally be under about 1 kDa. Biotin is a
conventional label or ligand, particularly analogs such as
dethiobiotin and deiminobiotin, which can be readily dis
placed from streptavidin by biotin. However, any small
molecule will suffice that can be captured and released under
convenient conditions.
Affinity purification of biological molecules, for example
proteins, is known in the art and allows the purification of
molecules by exploiting the binding affinity of the target
molecule for a molecular binding partner. Examples of
affinity purification methods are fusion tag protein purifica
tion, avidin-biotin system, pull-down assay and the like.
Drug Screening Assays
In another aspect, the subject technology provides assays
for screening test compounds that interfere with vimentin
binding to PAR-4 or which cause release of vimentin-bound
PAR-4. In a typical assay, cells, such as HEL cells, are
seeded onto an appropriate support, such as 60-mm plates
containing supplemented growth medium (e.g., supplemented with 0.1% serum) at a desired confluency, such as
40-70% confluency, and treated with the test compound
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(e.g., 500 nM) or control vehicle. The cells are allowed to
grow for a period of time, such as 24 hours, after which the
conditioned medium (CM) is concentrated (e.g., concen
trated 30x to 100 µl using Millipore tubes (Ami con Ultra
centrifugal filters, Ultracel-1OK) by 15 min centrifugation at
4500 rpm). The concentrated CM is then subjected to
co-immunoprecipitation using detectably labeled PAR-4 and
vimentin antibodies in the presence of various concentra
tions of purified PAR-4 and the precipitated proteins are
resolved by SDS-PAGE and analyzed by Western blot
analysis. The amount of immunoprecipitated PAR-4-vimen
tin complex is compared to that of control samples. For
example, chemiluminescent signals may be quantified in the
BIO-RAD Molecular Imager ChemiDoc XRS+Imaging sys
tem using Quantity One software. Induction of Par-4 secre
tion by the test drug (e.g., 500 nM), as judged by this
Western blot analysis procedure, will indicate dissociation of
Par-4 from vimentin. Additionally, experiments can be
undertaken to determine whether the test compound disrupts
the interaction between vimentin and Par-4 using any test
drug that shows elevated secretion of Par-4 by Western blot
analysis or other such assay. For such experiments, cells may
be treated with the test drug (e.g., 500 nM) or vehicle for an
appropriate period of time, such as 24 hours, and then cell
lysates are prepared and subjected to immunoprecipitation
using an appropriate amount of a Par-4 antibody, vimentin
antibody or control IgG antibody by using any standard
immunoprecipitation procedure. Following immunosup
pression, the complexes are resolved, preferably by Western
blot analysis as described above. If the drug inhibits the
binding of Par-4 to vimentin, it will be reflected in the lack
of co-immunoprecipitation of Par-4 with the vimentin anti
body, and co-immunoprecipitation of vimentin with the
Par-4 antibody.
EX AMPLES
The following examples are intended to further illustrate
certain preferred embodiments of the disclosure and are not
limiting in nature. Those skilled in the art will recognize, or
be able to ascertain, using no more than routine experimen
tation, numerous equivalents to the specific substances and
procedures described herein.
Materials and Methods
The following materials and methods were used for the
experiments described herein.
Chemistry: Nutlin-3a, an inhibitor of MDM2 that is
reported to bind directly to MDM2, release, stabilize and
activate p53, was acquired from Cayman Chemical Com
pany. Brefeldin A, N-benzyloxycarbonyl-Val- Ala- Asp(O
Me) fluoromethyl ketone (zVAD-fmk) and other chemicals
were purchased from Sigma Aldrich or Fisher Scientific or
were synthesized according to literature procedures. The
synthesis of Arylquin 1, which utilized 4-(N,N-dimethyl
amino)-2-aminobenzaldehyde in a Friedlander condensation
with 2-fluorophenylacetontrile (see Zhang, W., et al. ACS
Chem Biol 8, 796-803 (2013)), and other heterocyclic fami
lies is described in the synthesis section below. The con
densation of 2-amino-4-(N,N-dimethylamino )benzaldehyde
with 2-(2-fluorophenyl)acetyl chloride secured 7-(dimethyl
amino)-3-(2-fluorophenyl)quinolin-2(1H)-one, and treat
ment with Lawesson's reagent (see Goswami, A., et al.
Cancer Res 68, 6190-6198 (2008)) provided 7-(dimethyl
amino)-3-(2-fluorophenyl)quinoline-2(1H)-thione. S-alky
lation of this intermediate with (+)-biotinyl-iodoacetamidyl3,6-dioxaoctanediamine led to biotinylated Arylquin 9 (see
the synthesis section below). Solvents were used from
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commercial vendors without further purification unless oth
erwise noted. Nuclear magnetic resonance spectra were
determined on a Varian instrument ( 1 H, 400 MHz; 13 C, 100
Mz). High resolution electrospray ionization (ESI) mass
spectra were recorded on a LTQ-Orbitrap Velos mass spectrometer (Thermo Fisher Scientific, Waltham, Mass., USA).
The FT resolution was set at 100,000 (at 400 m/z). Samples
were introduced through direct infusion using a syringe
pump with a flow rate of 5 µUmin. MALDI mass spectra
were obtained on a Bruker Utraflexstreme time-of-flight
mass spectrometer (Billerica, Mass.), using DHB (2,5-dihy
droxybenzoic acid) matrix. Purity of compounds was estab
lished by combustion analyses by Atlantic Microlabs, Inc.,
Norcross, Ga. Compounds were chromatographed on pre
parative layer Merck silica gel F254 unless otherwise indicated.
Cells and plasmids: Human lung cancer cells H1299,
HOP92, A549, H460, mouse lung cancer cells LLCl, human
prostate cancer cells LNCaP, DU145, PC-3, and primary
human lung fibroblast cells HEL and epithelial cells HBEC
and BEAS-2B were from ATCC, MD; normal human pros
tate epithelial cells PrE and human prostate stromal cells PrS
were from Lonza Inc., Allendale, N.J. KP7B cells were from
Tyler Jacks, MIT, MA. PC-3 derivatives PC-3 MM2 were
from Sue-Hwa Lin, M.D. Anderson Cancer Center, Houston,
Tex. Par-4+/+ and Par-4_1_ MEFs were derived from wild
type and Par-4-null C57BL/6 mice generated by Taconic.
See Eckes, B., et al. J Cell Sci 113, 2455-2462 (2000).
Vimentin-null (Vim-1-) and wild type MEFs, as well as
vimentin-expressing (Vim+) and vimentin-deficient (Vim-)
SW13 cells were from Anthony Brown (Ohio State Univer
sity).
Antibodies and siRNA duplexes: Par-4 (R334), CollAl
(H-197), Vimentin (H-84) for Western blot; Vimentin
(RV202) for ICC and immunoprecipitation; GRP78 (N20),
CollAl (H-197), p53 (D0-1) and pan-cytokeratin (Cl)
antibodies were from Santa Cruz Biotechnology, Inc. Active
caspase 3 antibody (Asp175) (5A1E) and p53 antibody
(1C12) were from Cell Signaling. The �-actin antibody was
from Sigma Chemical Corp.
Pull down experiments: To identify the target protein for
compound Arylquin 1, pull-down experiments were per
formed as described previously. See Bargagna-Mohan, P., et
al. J Biol Chem 285, 7657-7669 (2010). MEFs or HEL cells
(grown to confluence in 15 cm plates) were lysed in 50 ml
lysis buffer (40 mM Hepes, pH 7.8; 140 mM NaCl; 10 mM
NaF; 10% Glycerol, 1 mM EDTA; 1% Triton 100), and the
lysates were pre-cleared at 4 ° C. for 1 h with 100 µL
streptavidin beads (Novagen, Strep-Tactin Superflow Aga
rose). Binding reactions were performed by incubating the
pre-cleared cell lysates with 50 µL beads±25 µg of bioti
nylated Arylquin 1 at 4 ° C. for 2 h. The beads were then
washed four times with buffer (40 mM Hepes, pH 7.8; 140
mM NaCl; 10 mM NaF; 10% Glycerol, 1 mM EDTA), and
bound protein was eluted with 50 µL of 2.5 mM Biotin/PBS.
Eluted proteins were resolved by SDS-PAGE and Coo
massie blue staining.
Co-Immunoprecipitation and Western blot analysis: Pro
tein extracted from cell lysates was filtered, pre-cleared with
25 µL (bed volume) of protein G-Sepharose beads and
immunoprecipitated with 1 µg of respective antibodies. The
eluted proteins were resolved by SDS-PAGE, and subjected
to Western blot analysis as described.
Apoptosis assays: Apoptotic nuclei were identified by
immunocytochemical (ICC) analysis for active caspase-3,
and nuclei were revealed by 4, 6-diamidino-2-phenylindole
(DAPI) staining. See Hebbar, N., Wang, C. & Rangnekar, V.
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M. J Cell Phys 227, 3715-3721 (2012) and Shrestha-Bhat
tarai, T., Hebbar, N. & Rangnekar, V. M. Cancer Cell 24, 3-5
(2013). A total of three independent experiments were
performed; and approximately 500 cells were scored in each
experiment for apoptosis under a fluorescent microscope.
Cell surface GRP78 expression on the cancer cell surface
was quantified by FACS analysis in the Flow Cytometry
Shared Resource Facility, Markey Cancer Center as previ
ously described. See Hebbar, N., Wang, C. & Rangnekar, V.
M. J Cell Phys 227, 3715-3721 (2012).
Animal experiments: C57BL/6 mice were injected via the
intraperitoneal route with Arylquin 1 (10 mg/kg body
weight) or com oil vehicle, and whole-blood samples were
collected 24 h later. Serum was separated from the blood
samples, heated at 56 ° C. to inactivate complement. Aliquots
of the mouse serum samples were added to the growth
medium (final 20% mouse serum) of normal and cancer cells
in culture and tested for induction of ex vivo apoptosis in
cancer cells. All animal procedures were performed with
University of Kentucky IACUC approval.
Computational modeling: Molecular modeling of vimen
tin binding with Arylquin 1 and the analogs was performed
by using the previously reported computational protocol. Ee
Hamza, A. et al., J Chem Inform Model 54, 1166-1173
(2014) and Hamza, A. & Zhan, C.-G. J Phys Chem B 113,
2896-2908 (2009). Briefly, each ligand was docked into the
binding cavity and the resulting poses were refined by
molecular dynamics (MD)-simulations. The most favorable
binding mode (with the lowest binding free energy), which
was identified in the docking procedure, was subjected to an
MD simulation for 1 ns at 298 K and used in binding free
energy calculations.
Statistical analysis: All experiments were performed in
triplicate to verify the reproducibility of the findings. The
results show a mean of at least 3 experiments±Standard
Deviation (s.d.). Statistical analyses were carried out with
Statistical Analysis System software (SAS Institute, Cary,
N.C.) and P values were calculated using the Student t test.
The effect of interaction between two different treatments
was analyzed using a two-way ANOVA model with data
normality and equality of variance assumptions.
Synthesis of Compounds
FIG. 1 illustrates a general scheme for the synthesis of
arylquins and depiction of Arylquin 1. Reagents: a, arylac
etonitrile, tert-BuOK, DMF, 90 ° C., 3-4 h; b, 2(2'-fluoro
phenyl)acetyl chloride, Et3 N, reflux 2 h and then K2C03 ,
DMF, 90 ° C., 4 h; c, 2,4-bis(4-methoxyphenyl)-2,4-dithi
oxo-1,3,2,4-dithiadiphosphetane (Lawesson' s reagent),
dioxane, reflux 5 h; d, ( +)-biotinyl-iodoacetamidyl-3,6-di
oxaoctanediamine, K2C03 , DMF, 12 h; e, POC13, reflux, 3
h; f, Zn, CH3 C02H, 75° C., 1 h.
General Procedure for the Synthesis of Arylquins. To a
solution of 2.38 mmol (1.3 equiv) of the appropriate benzyl
cyanide in 3 mL of anhydrous DMF at 0 ° C. was added 2.38
mmol (1.3 equiv) of potassium tert-butoxide. The mixture
was stirred for 15 min, and 1.83 mmol of appropriate
2-aminobenzaldehyde dissolved in 1 mL of anhydrous DMF
was added dropwise at 0 ° C. The mixture was warmed to 25 °
C. and stirred for 3-4 h at 90° C. After cooling the mixture
was quenched by pouring into water to afford a precipitate
that was collected and purified by recrystallization and/or
chromatography as noted for individual compounds
described below.
3-(2-Fluorophenyl)-N7,N7-dimethylquinoline-2,7-di
amine (Arylquin-1). Purified by recrystallization from etha
nol: Yield 83%, mp 159-160 ° C. 1H NMR (DMSO-d6): Ii
7.63 (s, lH), 7.50-7.41 (m, 3H), 7.33-7.28 (m, 2H), 6.86 (dd,
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lH, 11=8.8 Hz, 12=2.8 Hz), 6.61 (d, lH, 1=2.8 Hz), 5.67 (s,
2H, NH2), 3.00 (s, 6H). 13C NMR (DMSO-d6): ll 160.09 (d,
1=242.6 Hz), 156.25, 151.88, 149.72, 137.78, 132.37 (d,
1=3.l Hz), 130.26 (d, 1=7.6 Hz), 128.58, 125.92 (d, 1=16.0
Hz), 125.27 (d, 1=3.8 Hz), 116.47 (d, 1=22.1 Hz), 115.63,
114.33, 111.55, 104.16, 40.51 (two C). HRMS (ESI) calcd
for C 17H 17 FN3 [MH+]: 282.14010. Found: 282.14056.
Anal. Calcd for C 17H 1 6 FN3 : C, 72.58; H, 5.73. Found: C,
72.52; H, 5.79.
3-(3-Fluorophenyl)-N7,N7-dimethylquinoline-2,7-diamine (Arylquin 2) Purified by recrystallization from ethano!: Yield 84%, mp 147-148 ° C. 1H NMR (DMSO-d6): Ii
7.68 (s, lH), 7.53-7.48 (m, 2H), 7.34-7.30 (m, 2H), 7.237.18 (m, lH), 6.86 (dd, lH, 11=8.8 Hz, 12=2.4 Hz), 6.61 (d,
lH, 1=2.8 Hz), 5.69 (s, 2H, NH2), 3.00 (s, 6H). 13C NMR
(DMSO-d6): Ii 162.78 (d, 1=242.9 Hz), 155.85, 151.81,
149.48, 141.22 (d, 1=7.6 Hz), 137.03, 131.18 (d, 1=8.4 Hz),
128.69, 125.27 (d, 1=2.3 Hz), 119.17 (d, 1=2.3 Hz), 116.07,
115.93 (d, 1=21.3 Hz), 114.45 (d, 1=20.5 Hz), 111.63,
104.07, 40.48 (two C). HRMS (ESI) calcd for C 17H 17 FN3
[MH+]: 282.14010. Found: 282.14095. Anal. Calcd for
C 17H 1 6 FN3 : C, 72.58; H, 5.73. Found: C, 72.54; H, 5.64.
3-(4-Fluorophenyl)-N,N-dimethylquinoline-2,7-damine
(Arylquin 3) Purified by recrystallization from acetonitrile:
Yield 91%, mp 155-156 ° C. lH NMR (DMSO-d6): Ii 7.62
(s, lH), 7.53-7.48 (m, 3H), 7.31-7.27 (m, 2H), 6.85 (dd, lH,
11=9.2 Hz, 12=2.8 Hz), 6.61 (d, lH, 1=2.4 Hz), 5.74 (s, 2H,
NH2), 2.99 (s, 6H). 13C NMR (DMSO-d6): Ii 161.91 (d,
1=242.l Hz), 156.13, 151.68, 149.34, 136.78, 135.11,
131.22 (d, 1=8.3 Hz, two C), 128.55, 119.53, 116.16, 116.08
(d, 1=21.2 Hz, two C), 111.56, 104.16, 40.51 (two C).
HRMS (ESI) calcd for C17H17FN3 [MH+]: 282.14010.
Found: 282.14085. Anal. Calcd for C 17H 1 6 FN3 : C, 72.58; H,
5.73. Found: C, 72.31; H, 5.58.
7-(Dimethylamino)-3-(2-fluorophenyl)quinolin-2(1H)one (Arylquin 4) To a mixture of 1.00 g (6.09 mmol) of
2-amino-4-(dimethylamino)benzaldehyde 15 and 0.68 g
(6.70 mmol, 1.1 equiv) of triethylamine in dichloromethane
(10 mL), we added 1.05 g (6.09 mmol, 1 equiv) of 2-(2fluorophenyl)acetyl chloride dropwise over a 15 min period.
The mixture was stirred at reflux for 2 h. After cooling to the
room temperature, the mixture was washed with 30 mL of
water, and the organic layer was separated, dried over
anhydrous MgS04 and concentrated under reduced pressure.
The crude residue, obtained after concentration, was dissolved in DMF (10 mL) followed by addition of 1.01 g (7.31
mmol, 1.2 equiv) of K2C03 . The resulting mixture was
stirred at 90 ° C. for 4 h, poured into water and a precipitate
was collected by filtration and dried in vacuum. The product
was purified by recrystallization from acetonitrile to provide
1.38 g (80%) of 7-(dimethylamino)-3-(2-fluorophenyl)quinolin-2(1H)-one (Arylquin 4) as a pale yellow solid: m p
247-248 ° C. 1H NMR (DMSO-d6): ll 11.52 (s, lH), 7.79 (s,
lH), 7.51-7.47 (m, 2H), 7.40-7.35 (m, lH), 7.25-7.20 (m,
2H), 6.69 (dd, lH, 11=8.8 Hz, 12=2.4 Hz), 6.48 (d, lH, 1=2.4
Hz), 3.00 (s, 6H). 13C NMR (DMSO-d6): ll 160.88, 159.75
(d, 1=244.3 Hz), 151.75, 140.74, 139.69 (d, l=l.5 Hz),
131.89 (d, 1=3.8 Hz), 129.18 (d, 1=7.5 Hz), 128.97, 125.03
(d, 1=15.2 Hz), 123.89 (d, 1=3.0 Hz), 121.09, 115.32 (d,
1=22.0 Hz), 109.97, 108.65, 94.74, 39.76 (two C). HRMS
(ESI) calcd for C 17H 1 6 FN2 0 [MH+]: 283.12412. Found:
283.12473. Anal. Calcd for C 17H 15 FN2 0: C, 72.32; H, 5.36.
Found: C, 72.19; H, 5.41.
7-(Dimethylamino)-3-(2-fluorophenyl)quinoline-2(1H)thione (Arylquin 5) A mixture of 500 mg (1.77 mmol, 1
equiv) of 7-(dimethylamino)-3-(2-fluorophenyl)quinolin-2
(lH)-one (Arylquin 4) and 716 mg (1.77 mmol, 1 equiv) of
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Lawesson's reagent 16 in anhydrous 1,4-dioxane (10 mL)
was stirred at reflux for 5 h. After cooling, a precipitate was
collected, washed with 10% aqueous NaOH solution (5 mL)
and water and dried in vacuum. The product was purified by
recrystallization from acetonitrile to provide 350 mg (66%)
of 7-(dimethylamino)-3-(2-fluorophenyl)quinoline-2(1H)thione (Arylquin 5) as a pale yellow solid: mp 251-253 ° C.
1
H NMR (DMSO-d6): ll 13.24 (s, lH), 7.75 (s, lH), 7.58 (d,
lH, 1=9.2 Hz), 7.41-7.37 (m, 2H), 7.23-7.18 (m, 2H), 6.91
(dd, lH, 11=8.8 Hz, 12=1.8 Hz), 6.82 (d, lH, 1=1.8 Hz), 3.04
(s, 6H). 13C NMR (DMSO-d6): ll 179.45, 159.51 (d, 1=242.9
Hz), 152.16, 141.29, 135.82, 132.20 (d, 1=3.2 Hz), 129.87,
129.29 (d, 1=8.4 Hz), 128.81, 127.89 (d, 1=15.2 Hz), 123.75
(d, 1=3.1 Hz), 115.16 (d, 1=22.0 Hz), 113.76, 111.61, 94.50,
39.77 (two C). HRMS (ESI) calcd for C 17H 1 6 FN2S [MH+]:
299.10127. Found: 299.10176. Anal. Calcd for
C 17H 1 5 FN2S: C, 68.43; H, 5.07. Found: C, 68.23; H, 5.18.
3-(2-Fluorophenyl)-N,N-dimethylquinolin-7-amine
(Arylquin 6) A mixture of 500 mg (1.77 mmol, 1 equiv) of
7-(dimethylamino)-3-(2-fluorophenyl)quinolin-2(1H)-one
(Arylquin 4) and 5 mL of phosphoryl chloride (POCl3) was
refluxed for 3 h. The mixture was poured on to ice and
neutralized with 10% aqueous sodium carbonate solution at
0 ° C. A precipitate was collected by filtration, dried in vacuo
and purified by chromatography using 1:5 ethylacetatehexane (Rf=0.25) to afford 415 mg (78%) of 2-chloro-3-(2fluorophenyl)-N,N-dimethylquinolin-7-amine as a pale yellow solid: mp 170-172 ° C. 1H NMR (DMSO-d6): ll 8.20 (s,
lH), 7.83 (d, lH, 1=9.2 Hz), 7.54-7.46 (m, 2H), 7.36-7.29
(m, 3H), 6.95 (d, lH, 1=2.4 Hz), 3.09 (s, 6H). 13C NMR
(DMSO-d6): Ii 159.36 (d, 1=243.6 Hz), 151.97, 148.83,
148.76, 139.50, 132.05 (d, 1=3.0 Hz), 130.50 (d, 1=8.4 Hz),
128.59, 125.54 (d, 1=16.0 Hz), 125.51 (d, 1=3.8 Hz), 122.92,
118.79, 116.87, 115.52 (d, 1=21.2 Hz), 104.18, 39.86 (two
C). HRMS (ESI) calcd for C 17H 14CIFN2 [MH+]:
301.09023. Found: 301.08961. Anal. Calcd for
Cl 7H14CIFN2: C, 67.89; H, 4.69. Found: C, 67.76; H, 4.52.
To a solution of 200 mg (0.66 mmol) of 2-chloro-3-(2fluorophenyl)-N,N-dimethylquinolin-7-amine in 9 mL of
glacial acetic acid and 0.7 mL of water at 75 ° C. was added
174 mg (2.66 mmol, 4 equiv) of zinc powder. After 1 h, the
mixture was quenched by addition of 40% aqueous sodium
hydroxide solution to a pH of 9-10. The solution was
extracted with dichloromethane and the organic layer was
washed with water, dried over anhydrous MgS04 and concentrated under reduced pressure. The product was purified
by chromatography using 1:2 ethylacetate-hexane to afford
98 mg (55%) of 3-(2-fluorophenyl)-N,N-dimethylquinolin7-amine (Arylquin 6) as a pale yellow solid: mp 142-144° C.
lH NMR (DMSO-d6): Ii 8.86 (s, lH), 8.30 (s, lH), 7.84 (d,
lH, 1=8.8 Hz), 7.70-7.60 (m, lH), 7.48-7.43 (m, lH),
7.39-7.32 (m, 3H), 7.02 (d, lH, 1=2.4 Hz), 3.09 (s, 6H). 13C
NMR (DMSO-d6): Ii 159.33 (d, 1=244.3 Hz), 151.28,
150.24 (d, 1=3.8 Hz), 148.80, 134.71 (d, 1=3.0 Hz), 130.73
(d, 1=3.0 Hz), 129.61 (d, 1=8.4 Hz), 128.90, 125.75 (d,
1=13.6 Hz), 125.16 (d, 1=3.0 Hz), 123.78, 119.68, 116.78,
116.19 (d, 1=22.0 Hz), 105.53, 39.99 (two C). HRMS (ESI)
calcd for C17H15FN2 [MH+]: 267.12920. Found:
267.12839. Anal. Calcd for C 17H 1 5 FN2: C, 76.67; H, 5.68.
Found: C, 76.53; H, 5.52.
N7,N7-Dimethyl-3-phenylquinoline-2,7-diamine
(Arylquin 7) Purified by chromatography on silica gel using
1:10 methanol-dichloromethane (Rf=0.48): Yield 83%, mp
123-125 ° C. 1H NMR (DMSO-d6): ll 7.64 (s, lH), 7.52-7.46
(m, SH), 7.41-7.36 (m, lH), 6.86 (dd, lH, 11=8.6 Hz, 12=2.6
Hz), 6.62 (d, lH, 1=2.4 Hz), 3.00 (s, 6H). 13C NMR
(DMSO-d6): Ii 155.55, 151.25, 148.68, 138.28, 136.34,
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128.88 (two C), 128.66 (two C), 128.15, 127.29, 120.05,
115.77, 111.15, 103.63, 40.07 (two C). HRMS (ESI) calcd
for C17H18N3 [MH+]: 264.14952. Found: 264.15024.
Anal. Calcd for C17H17N3: C, 77.54; H, 6.51. Found: C,
77.27; H, 6.43.
3-(2-Fluorophenyl)quinolin-2-amine (Arylquin 8) Puri
fied by chromatography on silica gel using 1:10 methanol
dichloromethane (Rf=0.55): Yield 79%, mp 152-153° C. 1H
NMR (DMSO-d6): Ii 7.87 (s, lH), 7.70 (d, lH, 1 =8.0 Hz),
7.55-7.44 (m, 4H), 7.37-7.32 (m, 2H), 7.22-7.18 (m, lH),
6.03 (s, 2H, NH2). 13C NMR (DMSO-d6): Ii 159.56 (d,
1=243.6 Hz), 155.85, 147.59, 137.86, 131.77 (d, 1=3.3 Hz),
130.36 (d, 1=8.0 Hz), 129.52, 127.65, 124.95, 124.90,
124.77 (d, 1=16.1 Hz), 122.80, 121.59, 118.76, 116.11 (d,
1=22.2 Hz). HRMS (ESI) calcd for C15 H12FN2 [MH+]:
239.09790. Found: 239.09831. Anal. Calcd for C15H11FN2 :
C, 75.62; H, 4.65. Found: C, 72.39; H, 4.71.
N-(2-(2-(2-(2-(7-( dimethylamino)-3-(2-fluorophenyl)
quinolin-2-ylthio)acetamido)ethoxy)ethoxy)ethyl)-5-(2oxohexahydro-lH-thieno[3,4-d]imidazol-4-yl)pentanamide
(Biotinylated Arylquin 9). To a solution of 28 mg (0.092
mmol) of 7-(dimethylamino)-3-(2-fluorophenyl)quinoline-2
(lH)-thione in 1 mL ofDMF was added 15 mg (0.11 mmol,
1.2 equiv) of K2C03 and 50 mg (0.092 mmol) of (+)
biotinyl-iodoacetamidyl-3,6-dioxaoctanediamine. The mixture was stirred for 12 h at 25 ° C., poured into water,
extracted with dichloromethane, dried over anhydrous
MgS04 and concentrated under reduced pressure. The prod
uct was purified by chromatography 1:10 methanol-dichlo
romethane (Rf=0.25) to afford 29 mg (44%) ofbiotinylated
Arylquin 9 as a pale yellow solid: 1H NMR (DMSO-d6): Ii
8.03 (t, lH, 1=4.8 Hz), 7.70 (s, lH), 7.59 (d, lH, 1 =8.8 Hz),
7.44-7.35 (m, 2H), 7.23-7.14 (m, 2H), 7.08 (dd, lH, 11=8.8
Hz, 12=2.8 Hz), 7.00 (d, lH, 1=2.4 Hz), 6.42 (t, lH, 1=4.8
Hz), 6.07 (br s, lH), 5.07 (br s, lH), 4.43-4.40 (m, lH),
4.25-4.22 (m, lH), 3.92 (s, 2H), 3.48-3.46 (m, 2H), 3.433.39 (m, 2H), 3.32-3.28 (m, 6H), 3.21-3.19 (m, 2H), 3.12 (s,
6H), 3.09-3.05 (m, lH), 2.84 (dd, lH, 11=12.8 Hz, 12=4.8
Hz), 2.66 (d, lH, 1 =12.8 Hz), 2.14 (t, 2H, 1=8.0 Hz),
1.68-1.56 (m, 4H), 1.41-1.36 (m, 2H). 13C NMR (DMSOd6): Ii 173.32, 170.59, 163.70, 160.28, 157.28, 152.12,
149.30, 136.68, 132.41 (d, 1 =2.1 Hz), 130.71 (d, 1 =8.0 Hz),
128.67, 125.27 (d, 1=16.1 Hz), 124.45 (d, 1=3.4 Hz), 123.95,
118.38, 116.14 (d, 1=22.2 Hz), 115.46, 107.65, 105.43,
70.26, 70.15, 70.00, 69.92, 61.94, 60.29, 55.59, 40.72,
39.75, 39.23, 36.08, 33.82, 29.92, 28.31, 28.26, 27.72.
MALDI-TOF MS calcd for C35 H46FN 605 S2 [MH+]:
713.2955. Found: 713.2936.
Testing ofArylquinolines for Promoting Secretion of Par-4
To identify Par-4 secretagogues, we synthesized and
screened 3-arylquinolines as well as related quinolones and
quinothiolones for the secretion of Par-4 protein from nor
mal fibroblasts under conditions that are not toxic to the
cells.
Nutlin-3a, originally developed as an MDM2 inhibitor,
stimulated Par-4 secretion at micromolar levels in mouse
embryonic fibroblast (MEF) cells. The presence of halogen
substituents on an aromatic ring, two aromatic rings sepa
rated by a two-atom spacer (i.e., 1,2-diphenylethane subunit)
and a nitrogen-containing heterocycle (i.e., an imidazole
subunit) in Nutlin-3a enabled us to screen an in-house
library that possessed similar features, namely halogenated
aromatic rings separated by two-atom spacers (i.e., 1,2diphenylethene or stilbene subunits) and nitrogen-contain
ing heterocycles. Specifically, we focused on halogenated
3-arylquinolines, 3-arylquinolones, and 3-arylthioquinolo
nes, which possessed stilbene subunits and nitrogen-con-
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taining heterocyclic rings imbedded within their structures.
We screened representative members of each of these het
erocyclic families on a compound-by-compound basis for
the secretion ofPar-4 protein from normal mouse fibroblasts
under conditions that were not toxic to the cells. Initial
expectations were that these heterocycles would serve as
Nutlin-3a surrogates and inhibit MDM2, but studies
reported herein established a completely different mechanism of action, reflecting that the structural dissimilarities
between these heterocycles and Nutlin-3a outweighed the
similarities that led to their initial selection for screening.
Within this library of compounds, the fluorinated
3-arylquinolines proved particularly promising in promoting
Par-4 secretion. Structure-activity studies defined that
3-arylquinolines, such as Arylquin 1, was most active as the
leading member of a new class of "small-molecule" Par-4
secretagogues. Arylquin 1 produced a dose-dependent secre
tion in MEF cells. Arylquin 1 also induced robust secretion
of Par-4 in normal/immortalized human cells, but failed to
induce the secretion of Par-4 in a panel oflung tumor cells.
By contrast, prostate cancer cells showed induction ofPar-4
secretion with Arylquin 1 relative to vehicle control. Con
sistent with previous studies, Brefeldin A, which blocked
anterograde endoplasmic reticulum-Golgi traffic, inhibited
basal as well as Arylquin I-inducible Par-4 secretion. See
Hebbar, N., Wang, C. & Rangnekar, V. M. J Cell Phys 227,
3715-3721 (2012). These findings indicated that Arylquin 1
regulated Par-4 secretion via the classical secretory pathway.
To identify the molecular target responsible for the
observed Par-4 secretory activity, we synthesized a bioti
nylated Arylquin 9. Biotinylated Arylquin 9 was confirmed
experimentally to retain Par-4 secretory properties and was
then used in pull-down experiments for potential protein
targets in mouse fibroblasts (MEFs) and human fibroblasts
(HEL).
We identified vimentin, a cytoskeletal intermediate fila
ment protein, as its principal target. The binding of Par-4 to
vimentin was experimentally confirmed by co-immunopre
cipitation experiments: the Par-4 antibody co-immunopre
cipitated endogenous vimentin, and the vimentin antibody
co-immunoprecipitated endogenous Par-4. Immunocytochemical analysis confirmed that Par-4 co-localized with
vimentin. On the other hand, cells treated with Arylquin 1
showed neither Par-4 co-immunoprecipitation nor co-local
ization with vimentin, indicating that Arylquin 1 displaced
Par-4 from vimentin. This action of Arylquin 1 was not
associated with inhibition of vimentin expression, suggest
ing that Arylquin 1 may cause conformational changes in
vimentin to inhibit its ability to bind and sequester Par-4 or
compete for a hydrophobic binding region on vimentin
crucial for Par-4 binding. The differential regulation ofPar-4
secretion in normal and various cancer cells by Arylquin 1
may reflect distinct posttranslational modification patterns
of Par-4 and/or vimentin; studies are underway to address
the underlying mechanism.
Computer modeling using molecular dynamics simula
tions led to a minimum-energy structure in which Arylquin
1 binds tetrameric vimentin in a hydrophobic pocket that lies
between a pair of head-to-tail a-helical dimers. The spatial
arrangement of functional groups within Arylquin 1 was
ideally suited to stabilize binding to vimentin. Additional
modeling revealed that Arylquin 1 and its analogs examined
bind vimentin in the same orientation but with different
binding energies. The relative values of the calculated
binding energies are qualitatively consistent with experi
mental trends: Arylquin 1, Arylquin 6 and Arylquin 8 with
the largest binding energies promoted the highest levels of
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Par-4 secretion. The fluorine group in Arylquin 1 was
indispensable for activity, and the removal of the fluorine
was accompanied by reduced binding and concomitant loss
of Par-4 secretory.
Because targeting vimentin may induce apoptosis, we
tested normal cells and diverse cancer cells for apoptosis by
Arylquin 1. Arylquin 1 induced the dose-dependent apop
tosis in cancer cells but not in normal cells (FIG. 2).
Importantly, 500 nM amounts ofArylquin 1, which triggered
secretion of Par-4 from normal cells but not lung cancer
cells, did not directly induce apoptosis in normal or cancer
cells. By contrast, 500 nM amounts of Arylquin 1 induced
apoptosis of PC-3 cells and its derivative PC-3MM2, which
are sensitive to apoptosis by Par-4, but not in LNCaP or
DU145 cells, which are resistant to apoptosis by Par-4.
We next tested co-cultures of normal cells with cancer
cells for the apoptotic effect ofArylquin 1 at 500 nM, as this
low concentration induced the secretion of Par-4 from
normal cells yet did not induce apoptosis in normal or cancer
cells. Arylquin 1 treatment of the co-cultures containing
Par-4+/+ MEFs and cancer cells resulted in apoptosis of the
cancer cells, relative to vehicle-treatment (FIG. 3 top). Only
the cancer cells, but not normal HEL cells, underwent
apoptosis in such co-culture experiments. By contrast,
Arylquin 1 treatment of the co-cultures containing Par-4_1_
MEFs and cancer cells did not induce apoptosis. Paracrine
apoptosis induced in the cancer cells by Par-4, which was
secreted from Par-4+1+ MEFs but not Par-4_1_ MEFs in
response to Arylquin 1 treatment, was mediated via cell
surface GRP78 (FIG. 4). Moreover, vimentin-deficient cells
showed robust increase in secretion of pro-apoptotic Par-4
activity in the CM relative to counterpart wild type cells, and
Arylquin 1 did not further induce Par-4 secretion in these
cells (FIG. 5). Based on these findings, we infer that: (a)
vimentin sequestered Par-4 and prevented its secretion, and
(b) Arylquin 1 bound to vimentin and thereby altered the
vimentin-Par-4 association to facilitate Par-4 secretion.
To determine the physiological significance of these find
ings, we injected immunocompetent mice withArylquin 1 or
vehicle and examined their serum for circulating levels of
Par-4. Arylquin 1 produced 5-fold higher Par-4 secretion
relative to vehicle control in serum (FIG. 3 bottom). Serum
from the Arylquin 1 treated mice, but not vehicle-treated
mice, produced significantly higher (P<0.001) ex vivo apop
tosis of cancer cell cultures (FIG. 3 bottom). The proapoptotic activity in the serum was neutralized by the Par-4
antibody. These findings implied that systemic Par-4 levels
were elevated in response to Arylquin 1 treatment and that
these levels were effective in producing apoptosis of cancer
cells.
In summary, the present study identified a novel secret
agogue, Arylquin 1, that produced a dose-dependent secre
tion of Par-4 at nanomolar concentrations from both normal
fibroblasts and epithelial cells. Vimentin was the primary
target of Arylquin 1, as determined using a biotinylated
analog of Arylquin 1. Vimentin represents a particularly
important therapeutic target because of its elevation in
diverse tumors and its causal role in EMT and metastasis 12 .
Importantly, this chemical genetics approach led to the
identification of vimentin as a novel binding partner of Par-4
and indicated that Arylquin 1 exhibited its function by
binding to vimentin and releasing vimentin-bound Par-4 for
secretion. At low concentrations, Arylquin 1 by itself did not
kill normal cells and most cancer cells, but instead, it caused
robust secretion of Par-4 from normal cells and triggered
apoptosis in cancer cells only when they were used in
co-culture experiments with normal cells. These findings,

which implicated Par-4 secreted from normal cells in the
apoptotic death of cancer cells, were corroborated by the
observation that Arylquin 1 treatment of cancer cells co
cultured with Par-4-null normal cells failed to induce apop
tosis of the cancer cells. Thus, Arylquin 1 induced paracrine
apoptosis in cancer cells via Par-4 secreted by normal cells.
Because Par-4 produced apoptosis in diverse tumors and
because there were no previously reported compounds that
acted at nanomolar concentrations to produce the levels of
Par-4 secretion discovered in this study, these findings have
potential, translational significance.
While the claimed invention has been described in detail
and with reference to specific embodiments thereof, it will
be apparent to one of ordinary skill in the art that various
changes and modifications can be made to the claimed
invention without departing from the spirit and scope
thereof. Thus, for example, those skilled in the art will
recognize, or be able to ascertain, using no more than routine
experimentation, numerous equivalents to the specific sub
stances and procedures described herein. Such equivalents
are considered to be within the scope of this invention, and
are covered by the following claims.
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What is claimed is:
1. A method for alleviating, ameliorating, or lessening the
severity of cancer in a subject in need thereof comprising
administering to the subject an effective amount of the
compound of formula (I):
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(I)
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or a pharmaceutically acceptable salt thereof;
wherein n is 1, 2, 3, 4, 5, or 6, for each NR 1R2, R 1 and R2
are independently H, alkyl, alkoxy, aryl, heteroaryl; Ar
is aryl or heteroaryl, which can be further substituted
with halogen, amino, alkylamino, dialkylamino, aryl
alkylamino, N-oxides of dialkylamino, trialkylammonium, mercapto, alkylthio, alkanoyl, nitro, nitrosyl,
cyano, alkoxy, alkenyloxy, aryl, heteroaryl, sulfonyl,
sulfonamide, CONR3R4, NR3 CO(R4), NR3 COO(R4),
NR3 CONR4R5 where R3, R4, R5, are independently, H,
alkyl, aryl, heteroaryl or a fluorine; X represents halogen; m is 1, 2, 3, 4, or 5,
wherein the cancer is selected from prostate cancer or
lung cancer.
2. The method according to claim 1, wherein n is 2 and
one NR 1R2 group is at the 2 position of the quinoline ring
and the another NR 1R2 group is at the 7 position of the
quinoline ring and the Ar-Xm group is at the 3 position of
the quinoline ring.
3. The method according to claim 2, wherein m is 1 or 2,
Ar is phenyl and X is selected from fluoro or chloro.
4. The method according to claim 2, wherein Ar is
heteroaryl.
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5. A compound according to formula (I):
(I)
5

10

or a pharmaceutically acceptable salt thereof;
wherein n is 1, 2, 3, 4, 5, or 6, for each NR1 R2, R1 and R2
are independently H, alkyl, alkoxy, aryl, heteroaryl; Ar
is aryl or heteroaryl, which can be further substituted
with halogen, amino, alkylamino, dialkylamino, aryl
alkylamino, N-oxides of dialkylamino, trialkylammo
nium, mercapto, alkylthio, alkanoyl, nitro, nitrosyl,
cyano, alkoxy, alkenyloxy, aryl, heteroaryl, sulfonyl,
sulfonamide, CONR3 R4, NR3 CO(R4), NR3COO(R4),
NR3CONR4R5 where R3 , R4, R5 , are independently, H,
alkyl, aryl, heteroaryl or a fluorine; X represents halo
gen; m is 1, 2, 3, 4, or 5.
6. The compound of claim 5, wherein n is 1 or 2; for each
NR1 R2, R1 and R2 are independently H, or a lower alkyl; Ar
is phenyl; m is 1 or 2; and X is selected from fluoro or
chloro.
7. The compound of claim 5, wherein the compound is
3-(2-fluorophenyl)-N7 ,N7 -dimethylquinoline-2,7-diamine;
3-(3-fluorophenyl)-N7 ,N7 -dimethylquinoline-2,7-diamine;
3-(4-fluorophenyl)-N7 ,N7 -dimethylquinoline-2,7-diamine;
3-(2-fluorophenyl)-N,N-dimethylquinolin-7-amine; 3-(2fluorophenyl)quinolin-2-amine.
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8. A biotinylated derivative of the compound according to
claim 5.
9. A pharmaceutically acceptable composition comprising
a compound of claim 5 and a pharmaceutically acceptable
additive.
10. A method of alleviating, ameliorating, or lessening the
severity of cancer in a subject in need thereof comprising
administering to the subject an effective amount of a phar
maceutically acceptable composition of claim 9,
wherein the cancer is selected from prostate or lung
cancer.
11. The method of claim 1, wherein n is 2; R1 and R2 are
independently H, or alkyl; Ar is aryl substituted with alkoxy;
and m is 1; and wherein one NR1 R2 group is at the 2 position
of the quinoline ring and the another NR1 R2 group is at the
7 position of the quinoline ring and theAr-Xm group is a the
3 position of the quinoline ring and X is selected from the
fluoro or chorlo.
12. The compound of claim 5, wherein n is 2; R1 and R2
are independently H, or alkyl; Ar is aryl substituted with
alkoxy; and m is 1; and wherein one NR1 R2 group is at the
2 position of the quinoline ring and the another NR1 R2 group
is at the 7 position of the quinoline ring and theAr-Xm group
is at the 3 position of the quinoline ring and X is selected
from fluoro or chloro.
13. The pharmaceutically acceptable composition of
claim 9, wherein n is 2; R1 and R2 are independently H, or
alkyl; Ar is aryl substituted with alkoxy; and m is 1 ; and
wherein one NR1 R2 group is at the 2 position of the
quinoline ring and the another NR1 R2 group is at the 7
position of quinoline ring and the Ar-Xm group is at the 3
position of quinoline ring and X is selected from fluoro or
chloro.
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